[S02DA03, antipyrine, The metabolism of Antipyrine can be decreased when combined with Almotriptan.]
[J01GA01, streptomycin, Almotriptan may decrease the excretion rate of Streptomycin which could result in a higher serum level.]
[M03AB01, succinylcholine, The risk or severity of adverse effects can be increased when Succinylcholine is combined with Almotriptan.]
[A02BX02, sucralfate, Sucralfate may decrease the excretion rate of Almotriptan which could result in a higher serum level.]
[J01CG01, sulbactam, Almotriptan may decrease the excretion rate of Sulbactam which could result in a higher serum level.]
[J01EC02, sulfadiazine, The metabolism of Almotriptan can be decreased when combined with Sulfadiazine.]
[J01EC01, sulfamethoxazole, Almotriptan may decrease the excretion rate of Sulfamethoxazole which could result in a higher serum level.]
[M01AB02, sulindac, The risk or severity of hypertension can be increased when Sulindac is combined with Almotriptan.]
[N05AL01, sulpiride, The risk or severity of adverse effects can be increased when Almotriptan is combined with Sulpiride.]
[N03AX03, sulthiame, The risk or severity of adverse effects can be increased when Almotriptan is combined with Sulthiame.]
[M01AX04, apazone, The risk or severity of hypertension can be increased when Almotriptan is combined with Azapropazone.]
[L02BA01, tamoxifen, The metabolism of Tamoxifen can be decreased when combined with Almotriptan.]
[N05CD07, temazepam, The risk or severity of adverse effects can be increased when Temazepam is combined with Almotriptan.]
[R03CC03, terbutaline, The risk or severity of hypertension can be increased when Terbutaline is combined with Almotriptan.]
[B01AE07, dabigatran etexilate, Almotriptan may decrease the excretion rate of Dabigatran etexilate which could result in a higher serum level.]
[G03BA03, testosterone, Testosterone may decrease the excretion rate of Almotriptan which could result in a higher serum level.]
[N07XX06, tetrabenazine, The metabolism of Tetrabenazine can be decreased when combined with Almotriptan.]
[S01HA03, tetracaine, The risk or severity of adverse effects can be increased when Almotriptan is combined with Tetracaine.]
[S03AA02, tetracycline, Tetracycline may decrease the excretion rate of Almotriptan which could result in a higher serum level.]
[J01DI02, ceftaroline fosamil, Ceftaroline fosamil may decrease the excretion rate of Almotriptan which could result in a higher serum level.]
[N05AE05, lurasidone, The risk or severity of adverse effects can be increased when Almotriptan is combined with Lurasidone.]
[A04AD10, dronabinol, Dronabinol may increase the central nervous system depressant (CNS depressant) activities of Almotriptan.]
[N04BC07, apomorphine, The risk or severity of adverse effects can be increased when Apomorphine is combined with Almotriptan.]
[L04AX02, thalidomide, Almotriptan may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.]
[R03DA07, theobromine, Theobromine may increase the excretion rate of Almotriptan which could result in a lower serum level and potentially a reduction in efficacy.]
[R03DA04, theophylline, The metabolism of Theophylline can be decreased when combined with Almotriptan.]
[P02CA02, thiabendazole, Thiabendazole may decrease the excretion rate of Almotriptan which could result in a higher serum level.]
[R06AD03, thiethylperazine, The risk or severity of adverse effects can be increased when Almotriptan is combined with Thiethylperazine.]
[N05CA19, thiopental, The risk or severity of adverse effects can be increased when Thiopental is combined with Almotriptan.]
[N05AB08, thioproperazine, The risk or severity of adverse effects can be increased when Almotriptan is combined with Thioproperazine.]
[N05AC02, thioridazine, The metabolism of Almotriptan can be decreased when combined with Thioridazine.]
[N05AF04, thiothixene, The risk or severity of adverse effects can be increased when Almotriptan is combined with Thiothixene.]
[C01BB04, aprindine, The metabolism of Aprindine can be decreased when combined with Almotriptan.]
[G04BE06, moxisylyte, The risk or severity of hypertension can be increased when Almotriptan is combined with Moxisylyte.]
[N05AL03, tiapride, The risk or severity of adverse effects can be increased when Almotriptan is combined with Tiapride.]
[B01AC05, ticlopidine, The metabolism of Almotriptan can be decreased when combined with Ticlopidine.]
[N02AX01, tilidine, The risk or severity of adverse effects can be increased when Almotriptan is combined with Tilidine.]
[S01ED01, timolol, Almotriptan may decrease the antihypertensive activities of Timolol.]
[P01AB02, tinidazole, Tinidazole may decrease the excretion rate of Almotriptan which could result in a higher serum level.]
[S01AA12, tobramycin, Almotriptan may decrease the excretion rate of Tobramycin which could result in a higher serum level.]
[A10BB05, tolazamide, Tolazamide may decrease the excretion rate of Almotriptan which could result in a higher serum level.]
[M02AX02, tolazoline, Almotriptan may decrease the antihypertensive activities of Tolazoline.]
[V04CA01, tolbutamide, The metabolism of Tolbutamide can be decreased when combined with Almotriptan.]
[M02AA21, tolmetin, The risk or severity of hypertension can be increased when Tolmetin is combined with Almotriptan.]
[M03BX04, tolperisone, The risk or severity of adverse effects can be increased when Almotriptan is combined with Tolperisone.]
[N02AX02, tramadol, The risk or severity of serotonin syndrome can be increased when Almotriptan is combined with Tramadol.]
[N06AF04, tranylcypromine, The metabolism of Almotriptan can be decreased when combined with Tranylcypromine.]
[N06AX05, trazodone, The risk or severity of serotonin syndrome can be increased when Trazodone is combined with Almotriptan.]
[L01XF01, tretinoin, The metabolism of Almotriptan can be decreased when combined with Tretinoin.]
[C03DB02, triamterene, Triamterene may increase the excretion rate of Almotriptan which could result in a lower serum level and potentially a reduction in efficacy.]
[N05CD05, triazolam, The risk or severity of adverse effects can be increased when Triazolam is combined with Almotriptan.]
[C03AA06, trichlormethiazide, Trichlormethiazide may increase the excretion rate of Almotriptan which could result in a lower serum level and potentially a reduction in efficacy.]
[A03AB12, mepenzolate, Almotriptan may increase the central nervous system depressant (CNS depressant) activities of Mepenzolate.]
[A16AX12, trientine, Almotriptan may decrease the excretion rate of Triethylenetetramine which could result in a higher serum level.]
[N05AB06, trifluoperazine, The risk or severity of adverse effects can be increased when Almotriptan is combined with Trifluoperazine.]
[S01AD02, trifluridine, Trifluridine may decrease the excretion rate of Almotriptan which could result in a higher serum level.]
[N05AD02, trifluperidol, The risk or severity of adverse effects can be increased when Almotriptan is combined with Trifluperidol.]
[N05AA05, triflupromazine, Almotriptan may increase the central nervous system depressant (CNS depressant) activities of Triflupromazine.]
[N04AA01, trihexyphenidyl, Almotriptan may increase the central nervous system depressant (CNS depressant) activities of Trihexyphenidyl.]
[R03BA07, mometasone, The metabolism of Almotriptan can be decreased when combined with Mometasone.]
[A03AA05, trimebutine, Almotriptan may increase the central nervous system depressant (CNS depressant) activities of Trimebutine.]
[R06AD01, trimeprazine, The risk or severity of adverse effects can be increased when Almotriptan is combined with Alimemazine.]
[N03AC02, trimethadione, The risk or severity of adverse effects can be increased when Trimethadione is combined with Almotriptan.]
[C02BA01, trimethaphan, Almotriptan may decrease the antihypertensive activities of Trimethaphan.]
[J01EA01, trimethoprim, The metabolism of Almotriptan can be decreased when combined with Trimethoprim.]
[N06AA06, trimipramine, The metabolism of Trimipramine can be decreased when combined with Almotriptan.]
[R06AC04, tripelennamine, The metabolism of Almotriptan can be decreased when combined with Tripelennamine.]
[R06AX07, triprolidine, The risk or severity of adverse effects can be increased when Triprolidine is combined with Almotriptan.]
[A03BB01, butylscopolamine, Almotriptan may increase the central nervous system depressant (CNS depressant) activities of Butylscopolamine.]
[J01FA08, troleandomycin, The metabolism of Almotriptan can be decreased when combined with Troleandomycin.]
[N06AX24, vilazodone, The metabolism of Almotriptan can be decreased when combined with Vilazodone.]
[N06AX02, tryptophan, The risk or severity of adverse effects can be increased when Tryptophan is combined with Almotriptan.]
[C09CA09, azilsartan medoxomil, Almotriptan may decrease the antihypertensive activities of Azilsartan medoxomil.]
[M03AA02, tubocurarine, The risk or severity of adverse effects can be increased when Almotriptan is combined with Tubocurarine.]
[R03DX07, roflumilast, Almotriptan may decrease the excretion rate of Roflumilast which could result in a higher serum level.]
[L01FX04, ipilimumab, Almotriptan may decrease the excretion rate of Ipilimumab which could result in a higher serum level.]
[R02AA14, oxyquinoline, Almotriptan may decrease the excretion rate of Oxyquinoline which could result in a higher serum level.]
[L02BX03, abiraterone, The metabolism of Almotriptan can be decreased when combined with Abiraterone.]
[A10BH05, linagliptin, The metabolism of Almotriptan can be decreased when combined with Linagliptin.]
[J05AP03, boceprevir, The metabolism of Almotriptan can be decreased when combined with Boceprevir.]
[J05AP02, telaprevir, The metabolism of Almotriptan can be decreased when combined with Telaprevir.]
[J05AG05, rilpivirine, The metabolism of Almotriptan can be decreased when combined with Rilpivirine.]
[S01AA28, vancomycin, Almotriptan may decrease the excretion rate of Vancomycin which could result in a higher serum level.]
[N03AX21, ezogabine, The risk or severity of adverse effects can be increased when Almotriptan is combined with Ezogabine.]
[B01AF01, rivaroxaban, Almotriptan may decrease the excretion rate of Rivaroxaban which could result in a higher serum level.]
[R03AC18, indacaterol, The risk or severity of hypertension can be increased when Almotriptan is combined with Indacaterol.]
[C08DA01, verapamil, The metabolism of Almotriptan can be decreased when combined with Verapamil.]
[N06AX09, viloxazine, The metabolism of Almotriptan can be decreased when combined with Viloxazine.]
[L01CA01, vinblastine, The metabolism of Almotriptan can be decreased when combined with Vinblastine.]
[C04AX07, vincamine, Almotriptan may decrease the antihypertensive activities of Vincamine.]
[B03BA01, vitamin B12, Cyanocobalamin may decrease the excretion rate of Almotriptan which could result in a higher serum level.]
[B01AA03, warfarin, Almotriptan may decrease the excretion rate of Warfarin which could result in a higher serum level.]
[N01AX15, xenon, The risk or severity of hypertension can be increased when Almotriptan is combined with Xenon.]
[C03BA10, xipamide, Xipamide may increase the excretion rate of Almotriptan which could result in a lower serum level and potentially a reduction in efficacy.]
[J05AF01, zidovudine, The metabolism of Almotriptan can be decreased when combined with Zidovudine.]
[N05AF05, zuclopenthixol, The risk or severity of adverse effects can be increased when Almotriptan is combined with Zuclopenthixol.]
[J05AE02, indinavir, The metabolism of Almotriptan can be decreased when combined with Indinavir.]
[N03AX14, levetiracetam, The risk or severity of adverse effects can be increased when Almotriptan is combined with Levetiracetam.]
[L01EC01, vemurafenib, The metabolism of Almotriptan can be decreased when combined with Vemurafenib.]
[M05BA03, pamidronic acid, Pamidronic acid may decrease the excretion rate of Almotriptan which could result in a higher serum level.]
[M05BA05, tiludronic acid, Almotriptan may decrease the excretion rate of Tiludronic acid which could result in a higher serum level.]
[B06AC02, icatibant, Almotriptan may decrease the excretion rate of Icatibant which could result in a higher serum level.]
[L01ED01, crizotinib, The metabolism of Almotriptan can be decreased when combined with Crizotinib.]
[A02BC04, rabeprazole, Almotriptan may decrease the excretion rate of Rabeprazole which could result in a higher serum level.]
[N05AE04, ziprasidone, The risk or severity of adverse effects can be increased when Almotriptan is combined with Ziprasidone.]
[G03AC10, drospirenone, Drospirenone may increase the excretion rate of Almotriptan which could result in a lower serum level and potentially a reduction in efficacy.]
[V03AC02, deferiprone, Almotriptan may decrease the excretion rate of Deferiprone which could result in a higher serum level.]
[N02BA01, aspirin, The risk or severity of hypertension can be increased when Almotriptan is combined with Acetylsalicylic acid.]
[L01EJ01, ruxolitinib, Almotriptan may decrease the excretion rate of Ruxolitinib which could result in a higher serum level.]
[G04BD07, tolterodine, Almotriptan may increase the central nervous system depressant (CNS depressant) activities of Tolterodine.]
[J01DH04, doripenem, Almotriptan may decrease the excretion rate of Doripenem which could result in a higher serum level.]
[C07AB03, atenolol, Almotriptan may decrease the antihypertensive activities of Atenolol.]
[J02AC03, voriconazole, The metabolism of Almotriptan can be decreased when combined with Voriconazole.]
[M03AC04, atracurium, The risk or severity of adverse effects can be increased when Almotriptan is combined with Atracurium.]
[S01FA01, atropine, Almotriptan may increase the central nervous system depressant (CNS depressant) activities of Atropine.]
[M01CB03, auranofin, Almotriptan may decrease the excretion rate of Auranofin which could result in a higher serum level.]
[B03XA04, peginesatide, Almotriptan may decrease the excretion rate of Peginesatide which could result in a higher serum level.]
[L01BC07, azacitidine, Almotriptan may decrease the excretion rate of Azacitidine which could result in a higher serum level.]
[L04AX01, azathioprine, Almotriptan may decrease the excretion rate of Azathioprine which could result in a higher serum level.]
[L01BC05, gemcitabine, Gemcitabine may decrease the excretion rate of Almotriptan which could result in a higher serum level.]
[J01DF01, aztreonam, Aztreonam may decrease the excretion rate of Almotriptan which could result in a higher serum level.]
[R02AB04, bacitracin, Bacitracin may decrease the excretion rate of Almotriptan which could result in a higher serum level.]
[G04BE10, avanafil, The serum concentration of Avanafil can be increased when it is combined with Almotriptan.]
[M03BX01, baclofen, Baclofen may increase the central nervous system depressant (CNS depressant) activities of Almotriptan.]
[A08AA11, lorcaserin, The metabolism of Almotriptan can be decreased when combined with Lorcaserin.]
[G04BD12, mirabegron, The serum concentration of Almotriptan can be increased when it is combined with Mirabegron.]
[V03AX03, cobicistat, The metabolism of Almotriptan can be decreased when combined with Cobicistat.]
[J05AJ02, elvitegravir, The metabolism of Almotriptan can be decreased when combined with Elvitegravir.]
[L02BB04, enzalutamide, The serum concentration of Almotriptan can be decreased when it is combined with Enzalutamide.]
[L01EA04, bosutinib, The metabolism of Almotriptan can be decreased when combined with Bosutinib.]
[L04AA31, teriflunomide, The metabolism of Almotriptan can be decreased when combined with Teriflunomide.]
[C01CA18, octopamine, The risk or severity of hypertension can be increased when Almotriptan is combined with Octopamine.]
[N05CA04, barbital, The risk or severity of adverse effects can be increased when Almotriptan is combined with Barbital.]
[D02BA02, octinoxate, Almotriptan may decrease the excretion rate of Octinoxate which could result in a higher serum level.]
[J05AE04, nelfinavir, The metabolism of Almotriptan can be decreased when combined with Nelfinavir.]
[S01GA07, brimonidine, Brimonidine may increase the central nervous system depressant (CNS depressant) activities of Almotriptan.]
[N04BD02, rasagiline, The metabolism of Almotriptan can be decreased when combined with Rasagiline.]
[C08CA13, lercanidipine, Almotriptan may decrease the antihypertensive activities of Lercanidipine.]
[A03FA09, mosapride, The risk or severity of adverse effects can be increased when Almotriptan is combined with Mosapride.]
[N06DA02, donepezil, The risk or severity of adverse effects can be increased when Donepezil is combined with Almotriptan.]
[N03AX22, perampanel, Perampanel may increase the central nervous system depressant (CNS depressant) activities of Almotriptan.]
[N02CC03, zolmitriptan, The risk or severity of vasospastic reactions can be increased when Almotriptan is combined with Zolmitriptan.]
[R06AC06, thonzylamine, Almotriptan may increase the central nervous system depressant (CNS depressant) activities of Thonzylamine.]
[G04BD10, darifenacin, The metabolism of Almotriptan can be decreased when combined with Darifenacin.]
[V09IX04, fluorodeoxyglucose F18, Almotriptan may decrease the excretion rate of Fludeoxyglucose (18F) which could result in a higher serum level.]
[N01AA01, ethyl ether, The risk or severity of adverse effects can be increased when Almotriptan is combined with Diethyl ether.]
[L01EX07, cabozantinib, The metabolism of Almotriptan can be decreased when combined with Cabozantinib.]
[G04BE03, sildenafil, The metabolism of Almotriptan can be decreased when combined with Sildenafil.]
[V08CA11, gadofosveset, Almotriptan may decrease the excretion rate of Gadofosveset trisodium which could result in a higher serum level.]
[L01EA05, ponatinib, The metabolism of Ponatinib can be decreased when combined with Almotriptan.]
[B01AF02, apixaban, The metabolism of Apixaban can be decreased when combined with Almotriptan.]
[A16AX08, teduglutide, Almotriptan may decrease the excretion rate of Teduglutide which could result in a higher serum level.]
[A10BH04, alogliptin, Almotriptan may decrease the excretion rate of Alogliptin which could result in a higher serum level.]
[A16AX09, glycerol phenylbutyrate, The metabolism of Almotriptan can be decreased when combined with Glycerol phenylbutyrate.]
[C03AA01, bendroflumethiazide, Bendroflumethiazide may increase the excretion rate of Almotriptan which could result in a lower serum level and potentially a reduction in efficacy.]
[L04AX06, pomalidomide, The risk or severity of adverse effects can be increased when Almotriptan is combined with Pomalidomide.]
[G03XC05, ospemifene, The metabolism of Almotriptan can be decreased when combined with Ospemifene.]
[N02BA10, benorilate, The risk or severity of hypertension can be increased when Almotriptan is combined with Benorilate.]
[N05AD07, benperidol, The risk or severity of adverse effects can be increased when Almotriptan is combined with Benperidol.]
[A10BK02, canagliflozin, Canagliflozin may increase the excretion rate of Almotriptan which could result in a lower serum level and potentially a reduction in efficacy.]
[A06AX06, tegaserod, The metabolism of Almotriptan can be decreased when combined with Tegaserod.]
[R02AD01, benzocaine, The risk or severity of adverse effects can be increased when Almotriptan is combined with Benzocaine.]
[L03AA12, ancestim, Almotriptan may decrease the excretion rate of Ancestim which could result in a higher serum level.]
[M01AH01, celecoxib, The metabolism of Almotriptan can be decreased when combined with Celecoxib.]
[N02CC02, naratriptan, The risk or severity of adverse effects can be increased when Almotriptan is combined with Naratriptan.]
[L04AA18, everolimus, The metabolism of Almotriptan can be decreased when combined with Everolimus.]
[N04AC01, benztropine, Almotriptan may increase the central nervous system depressant (CNS depressant) activities of Benzatropine.]
[L01EC02, dabrafenib, The serum concentration of Almotriptan can be decreased when it is combined with Dabrafenib.]
[R02AX03, benzydamine, The risk or severity of hypertension can be increased when Almotriptan is combined with Benzydamine.]
[L01EE01, trametinib, The metabolism of Almotriptan can be decreased when combined with Trametinib.]
[P03AX06, benzyl alcohol, The risk or severity of adverse effects can be increased when Almotriptan is combined with Benzyl alcohol.]
[V09AX05, florbetapir F-18, Almotriptan may decrease the excretion rate of Florbetapir (18F) which could result in a higher serum level.]
[N06AX28, levomilnacipran, The risk or severity of adverse effects can be increased when Almotriptan is combined with Levomilnacipran.]
[C08EA02, bepridil, The metabolism of Almotriptan can be decreased when combined with Bepridil.]
[C02KX05, riociguat, The metabolism of Riociguat can be decreased when combined with Almotriptan.]
[A10BJ03, lixisenatide, Almotriptan may decrease the excretion rate of Lixisenatide which could result in a higher serum level.]
[C02KX04, macitentan, Almotriptan may decrease the antihypertensive activities of Macitentan.]
[L01EL01, ibrutinib, The metabolism of Ibrutinib can be decreased when combined with Almotriptan.]
[N06AX26, vortioxetine, The risk or severity of adverse effects can be increased when Almotriptan is combined with Vortioxetine.]
[G03AC08, etonogestrel, Etonogestrel may decrease the excretion rate of Almotriptan which could result in a higher serum level.]
[N03AF04, eslicarbazepine, The risk or severity of adverse effects can be increased when Almotriptan is combined with Eslicarbazepine.]
[J05AP05, simeprevir, The metabolism of Almotriptan can be decreased when combined with Simeprevir.]
[J05AP08, sofosbuvir, Almotriptan may decrease the excretion rate of Sofosbuvir which could result in a higher serum level.]
[N03AG04, vigabatrin, The risk or severity of adverse effects can be increased when Almotriptan is combined with Vigabatrin.]
[A10BK01, dapagliflozin, Dapagliflozin may increase the excretion rate of Almotriptan which could result in a lower serum level and potentially a reduction in efficacy.]
[C01CA27, droxidopa, Almotriptan may increase the hypertensive activities of Droxidopa.]
[C07AB04, acebutolol, The metabolism of Almotriptan can be decreased when combined with Acebutolol.]
[N05CH03, tasimelteon, The risk or severity of adverse effects can be increased when Almotriptan is combined with Tasimelteon.]
[A16AA07, metreleptin, The metabolism of Almotriptan can be increased when combined with Metreleptin.]
[L04AA32, apremilast, The metabolism of Almotriptan can be increased when combined with Apremilast.]
[L02BG02, formestane, Almotriptan may decrease the excretion rate of Formestane which could result in a higher serum level.]
[S03BA03, betamethasone, The metabolism of Almotriptan can be increased when combined with Betamethasone.]
[S01ED02, betaxolol, Almotriptan may decrease the antihypertensive activities of Betaxolol.]
[V03AB34, fomepizole, Almotriptan may decrease the excretion rate of Fomepizole which could result in a higher serum level.]
[C02CC01, bethanidine, Almotriptan may decrease the antihypertensive activities of Bethanidine.]
[C10AB02, bezafibrate, The metabolism of Almotriptan can be decreased when combined with Bezafibrate.]
[L04AC11, siltuximab, The metabolism of Almotriptan can be increased when combined with Siltuximab.]
[A03BA03, hyoscyamine, Almotriptan may increase the central nervous system depressant (CNS depressant) activities of Hyoscyamine.]
[B01AA07, acenocoumarol, The risk or severity of adverse effects can be increased when Almotriptan is combined with Acenocoumarol.]
[N01AX05, alfaxalone, The risk or severity of adverse effects can be increased when Almotriptan is combined with Alfaxalone.]
[R03AC19, olodaterol, The metabolism of Olodaterol can be decreased when combined with Almotriptan.]
[V08AA01, diatrizoic acid, Diatrizoate may decrease the excretion rate of Almotriptan which could result in a higher serum level.]
[D11AA01, glycopyrronium, Almotriptan may increase the central nervous system depressant (CNS depressant) activities of Glycopyrronium.]
[V08AA04, iothalamic acid, Diatrizoate may decrease the excretion rate of Almotriptan which could result in a higher serum level.]
[N05CM19, suvorexant, Almotriptan may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.]
[A16AX10, eliglustat, The metabolism of Almotriptan can be decreased when combined with Eliglustat.]
[J01XA05, oritavancin, The metabolism of Almotriptan can be decreased when combined with Oritavancin.]
[S01AA15, dihydrostreptomycin, Dihydrostreptomycin may decrease the excretion rate of Almotriptan which could result in a higher serum level.]
[N05AA04, acepromazine, The risk or severity of adverse effects can be increased when Almotriptan is combined with Acepromazine.]
[N04AA02, biperiden, Almotriptan may increase the central nervous system depressant (CNS depressant) activities of Biperiden.]
[L04AX05, pirfenidone, The metabolism of Pirfenidone can be decreased when combined with Almotriptan.]
[S03AA06, gentamicin, Almotriptan may decrease the excretion rate of Gentamicin which could result in a higher serum level.]
[J05AP09, dasabuvir, The metabolism of Dasabuvir can be decreased when combined with Almotriptan.]
[B01AA01, dicumarol, The risk or severity of adverse effects can be increased when Almotriptan is combined with Dicoumarol.]
[B01AF03, edoxaban, Almotriptan may decrease the excretion rate of Edoxaban which could result in a higher serum level.]
[N06AX11, mirtazapine, Almotriptan may increase the serotonergic activities of Mirtazapine.]
[L04AC10, secukinumab, The metabolism of Almotriptan can be increased when combined with Secukinumab.]
[L01XH03, panobinostat, The metabolism of Almotriptan can be decreased when combined with Panobinostat.]
[N02BE01, acetaminophen, Acetaminophen may decrease the excretion rate of Almotriptan which could result in a higher serum level.]
[L01DC01, bleomycin, Bleomycin may decrease the excretion rate of Almotriptan which could result in a higher serum level.]
[A03AA09, difemerine, Almotriptan may increase the central nervous system depressant (CNS depressant) activities of Difemerine.]
[B01AA11, tioclomarol, The risk or severity of adverse effects can be increased when Almotriptan is combined with Tioclomarol.]
[J05AF08, adefovir dipivoxil, Adefovir dipivoxil may decrease the excretion rate of Almotriptan which could result in a higher serum level.]
[J05AP06, asunaprevir, The metabolism of Almotriptan can be decreased when combined with Asunaprevir.]
[A07DA06, eluxadoline, The risk or severity of serotonin syndrome can be increased when Almotriptan is combined with Eluxadoline.]
[N05AX16, brexpiprazole, The risk or severity of adverse effects can be increased when Almotriptan is combined with Brexpiprazole.]
[A04AD14, rolapitant, The metabolism of Almotriptan can be decreased when combined with Rolapitant.]
[G02CX02, flibanserin, The risk or severity of adverse effects can be increased when Almotriptan is combined with Flibanserin.]
[N05AX15, cariprazine, The risk or severity of adverse effects can be increased when Almotriptan is combined with Cariprazine.]
[M02AA25, aceclofenac, The risk or severity of hypertension can be increased when Almotriptan is combined with Aceclofenac.]
[M01AB11, acemetacin, The risk or severity of hypertension can be increased when Almotriptan is combined with Acemetacin.]
[S01EC01, acetazolamide, The risk or severity of adverse effects can be increased when Acetazolamide is combined with Almotriptan.]
[N05AB07, acetophenazine, The risk or severity of adverse effects can be increased when Almotriptan is combined with Acetophenazine.]
[A02BC03, lansoprazole, The metabolism of Almotriptan can be decreased when combined with Lansoprazole.]
[V03AB37, idarucizumab, Almotriptan may decrease the excretion rate of Idarucizumab which could result in a higher serum level.]
[L01CX01, trabectedin, The metabolism of Trabectedin can be decreased when combined with Almotriptan.]
[J02AC05, isavuconazole, The metabolism of Almotriptan can be decreased when combined with Isavuconazole.]
[J05AF13, tenofovir alafenamide, The serum concentration of Tenofovir alafenamide can be increased when it is combined with Almotriptan.]
[L01XG03, ixazomib, Almotriptan may decrease the excretion rate of Ixazomib which could result in a higher serum level.]
[B01AC27, selexipag, The metabolism of Selexipag can be decreased when combined with Almotriptan.]
[M04AB05, lesinurad, Almotriptan may decrease the excretion rate of Lesinurad which could result in a higher serum level.]
[N05CA05, aprobarbital, The risk or severity of adverse effects can be increased when Almotriptan is combined with Aprobarbital.]
[M01AE16, alminoprofen, The risk or severity of hypertension can be increased when Almotriptan is combined with Alminoprofen.]
[N03AX23, brivaracetam, The risk or severity of adverse effects can be increased when Almotriptan is combined with Brivaracetam.]
[L01XX52, venetoclax, The metabolism of Almotriptan can be decreased when combined with Venetoclax.]
[N05BA08, bromazepam, The risk or severity of adverse effects can be increased when Almotriptan is combined with Bromazepam.]
[N04BC01, bromocriptine, Bromocriptine may increase the vasoconstricting activities of Almotriptan.]
[A02AD05, aluminum magnesium silicate, Almotriptan may decrease the excretion rate of Almasilate which could result in a higher serum level.]
[A03AX08, alverine, The risk or severity of adverse effects can be increased when Almotriptan is combined with Alverine.]
[R06AB01, brompheniramine, The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Almotriptan.]
[N06AA19, amineptin, The risk or severity of adverse effects can be increased when Almotriptan is combined with Amineptine.]
[C08CA01, amlodipine, Almotriptan may decrease the antihypertensive activities of Amlodipine.]
[N06BX11, aniracetam, The risk or severity of adverse effects can be increased when Almotriptan is combined with Aniracetam.]
[C03CA02, bumetanide, Bumetanide may increase the excretion rate of Almotriptan which could result in a lower serum level and potentially a reduction in efficacy.]
[N01BB01, bupivacaine, The risk or severity of adverse effects can be increased when Bupivacaine is combined with Almotriptan.]
[C07AA19, bupranolol, Almotriptan may decrease the antihypertensive activities of Bupranolol.]
[N07BC01, buprenorphine, Almotriptan may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.]
[N05BE01, buspirone, The risk or severity of adverse effects can be increased when Buspirone is combined with Almotriptan.]
[L01XX27, arsenic trioxide, Almotriptan may decrease the excretion rate of Arsenic trioxide which could result in a higher serum level.]
[M02AA03, clofezone, Almotriptan may decrease the excretion rate of Rabeprazole which could result in a higher serum level.]
[N02AF01, butorphanol, The risk or severity of adverse effects can be increased when Butorphanol is combined with Almotriptan.]
[S01GX07, azelastine, Almotriptan may increase the central nervous system depressant (CNS depressant) activities of Azelastine.]
[L01XK03, rucaparib, The metabolism of Almotriptan can be decreased when combined with Rucaparib.]
[L01EF02, ribociclib, The metabolism of Almotriptan can be decreased when combined with Ribociclib.]
[A07EC04, balsalazide, The risk or severity of hypertension can be increased when Almotriptan is combined with Balsalazide.]
[R03CC12, bambuterol, The risk or severity of hypertension can be increased when Almotriptan is combined with Bambuterol.]
[A06AH05, naldemedine, Almotriptan may decrease the excretion rate of Naldemedine which could result in a higher serum level.]
[N07XX16, deutetrabenazine, Almotriptan may decrease the excretion rate of Deutetrabenazine which could result in a higher serum level.]
[N02BF02, pregabalin, The therapeutic efficacy of Almotriptan can be increased when used in combination with Pregabalin.]
[N03AX30, beclamide, The risk or severity of adverse effects can be increased when Almotriptan is combined with Beclamide.]
[C09AA07, benazepril, Almotriptan may decrease the antihypertensive activities of Benazepril.]
[S01HA02, benoxinate, The risk or severity of adverse effects can be increased when Oxybuprocaine is combined with Almotriptan.]
[P01CA02, benznidazole, Almotriptan may decrease the excretion rate of Benznidazole which could result in a higher serum level.]
[J01XX08, linezolid, The risk or severity of serotonin syndrome can be increased when Linezolid is combined with Almotriptan.]
[J05AF06, abacavir, Almotriptan may decrease the excretion rate of Abacavir which could result in a higher serum level.]
[J05AE09, tipranavir, The metabolism of Almotriptan can be decreased when combined with Tipranavir.]
[N07XX13, valbenazine, Almotriptan may decrease the excretion rate of Valbenazine which could result in a higher serum level.]
[L04AB02, infliximab, The metabolism of Almotriptan can be increased when combined with Infliximab.]
[L01EX10, midostaurin, The metabolism of Almotriptan can be decreased when combined with Midostaurin.]
[L01ED04, brigatinib, The metabolism of Brigatinib can be decreased when combined with Almotriptan.]
[N04BD03, safinamide, The metabolism of Almotriptan can be decreased when combined with Safinamide.]
[J01MA23, delafloxacin, Almotriptan may decrease the excretion rate of Delafloxacin which could result in a higher serum level.]
[L01BC06, capecitabine, Almotriptan may decrease the excretion rate of Capecitabine which could result in a higher serum level.]
[L01XX59, enasidenib, The metabolism of Enasidenib can be decreased when combined with Almotriptan.]
[C07AB07, bisoprolol, Almotriptan may decrease the antihypertensive activities of Bisoprolol.]
[R03AC17, bitolterol, The risk or severity of hypertension can be increased when Bitolterol is combined with Almotriptan.]
[J05AG03, efavirenz, The metabolism of Almotriptan can be decreased when combined with Efavirenz.]
[J01DC10, cefprozil, Cefprozil may decrease the excretion rate of Almotriptan which could result in a higher serum level.]
[C07AA17, bopindolol, The metabolism of Bopindolol can be decreased when combined with Almotriptan.]
[N04AA11, bornaprine, Almotriptan may increase the central nervous system depressant (CNS depressant) activities of Bornaprine.]
[N05AD06, bromperidol, The risk or severity of adverse effects can be increased when Almotriptan is combined with Bromperidol.]
[N05CD09, brotizolam, The risk or severity of adverse effects can be increased when Almotriptan is combined with Brotizolam.]
[C03DA03, canrenone, Canrenone may increase the excretion rate of Almotriptan which could result in a lower serum level and potentially a reduction in efficacy.]
[R03BA02, budesonide, Almotriptan may decrease the excretion rate of Budesonide which could result in a higher serum level.]
[C04AX20, buflomedil, The risk or severity of hypertension can be increased when Almotriptan is combined with Buflomedil.]
[M01AB07, bumadizone, The risk or severity of hypertension can be increased when Almotriptan is combined with Bumadizone.]
[N05CA03, butobarbital, The risk or severity of adverse effects can be increased when Almotriptan is combined with Butobarbital.]
[J05AX18, letermovir, The metabolism of Almotriptan can be decreased when combined with Letermovir.]
[N06AA15, butriptyline, The risk or severity of adverse effects can be increased when Almotriptan is combined with Butriptyline.]
[N01BX04, capsaicin, The metabolism of Almotriptan can be decreased when combined with Capsaicin.]
[A10BK04, ertugliflozin, Ertugliflozin may increase the excretion rate of Almotriptan which could result in a lower serum level and potentially a reduction in efficacy.]
[N05CA08, butylvinal, The risk or severity of adverse effects can be increased when Almotriptan is combined with Vinylbital.]
[R06AX18, acrivastine, Almotriptan may decrease the excretion rate of Acrivastine which could result in a higher serum level.]
[C09AA01, captopril, Almotriptan may decrease the antihypertensive activities of Captopril.]
[L02BB05, apalutamide, The metabolism of Almotriptan can be increased when combined with Apalutamide.]
[N03AF01, carbamazepine, The metabolism of Almotriptan can be increased when combined with Carbamazepine.]
[A03AA03, camylofine, Almotriptan may increase the central nervous system depressant (CNS depressant) activities of Camylofin.]
[R06AA08, carbinoxamine, The risk or severity of adverse effects can be increased when Carbinoxamine is combined with Almotriptan.]
[C07AG02, carvedilol, Almotriptan may decrease the antihypertensive activities of Carvedilol.]
[N03AX24, cannabidiol, The risk or severity of adverse effects can be increased when Cannabidiol is combined with Almotriptan.]
[B02BX08, avatrombopag, The metabolism of Almotriptan can be increased when combined with Avatrombopag.]
[L04AA37, baricitinib, Almotriptan may decrease the excretion rate of Baricitinib which could result in a higher serum level.]
[J01DE01, cefepime, Cefepime may decrease the excretion rate of Almotriptan which could result in a higher serum level.]
[J01DD10, cefetamet, Cefetamet may decrease the excretion rate of Almotriptan which could result in a higher serum level.]
[J01DD09, cefodizime, Cefodizime may decrease the excretion rate of Almotriptan which could result in a higher serum level.]
[J01DC11, ceforanide, Ceforanide may decrease the excretion rate of Almotriptan which could result in a higher serum level.]
[J01DD13, cefpodoxime, Cefpodoxime may decrease the excretion rate of Almotriptan which could result in a higher serum level.]
[L01EC03, encorafenib, The metabolism of Encorafenib can be decreased when combined with Almotriptan.]
[J01DD14, ceftibuten, Ceftibuten may decrease the excretion rate of Almotriptan which could result in a higher serum level.]
[J01GB14, plazomicin, Almotriptan may decrease the excretion rate of Plazomicin which could result in a higher serum level.]
[C07AB08, celiprolol, Almotriptan may decrease the antihypertensive activities of Celiprolol.]
[H01CC03, elagolix, The metabolism of Elagolix can be decreased when combined with Almotriptan.]
[L01XX62, ivosidenib, The metabolism of Almotriptan can be increased when combined with Ivosidenib.]
[P01BA07, tafenoquine, The metabolism of Tafenoquine can be decreased when combined with Almotriptan.]
[A16AX14, migalastat, Almotriptan may decrease the excretion rate of Migalastat which could result in a higher serum level.]
[N03AX17, stiripentol, The metabolism of Almotriptan can be decreased when combined with Stiripentol.]
[J05AX24, tecovirimat, The metabolism of Almotriptan can be increased when combined with Tecovirimat.]
[L01EB07, dacomitinib, The metabolism of Dacomitinib can be decreased when combined with Almotriptan.]
[S01GX12, cetirizine, The risk or severity of adverse effects can be increased when Cetirizine is combined with Almotriptan.]
[N05CM04, carbromal, The risk or severity of adverse effects can be increased when Almotriptan is combined with Carbromal.]
[N01BA04, chloroprocaine, The risk or severity of adverse effects can be increased when Almotriptan is combined with Chloroprocaine.]
[D08AE05, chloroxylenol, Almotriptan may decrease the excretion rate of Chloroxylenol which could result in a higher serum level.]
[R06AA06, chlorphenoxamine, Almotriptan may increase the central nervous system depressant (CNS depressant) activities of Chlorphenoxamine.]
[M01AC05, lornoxicam, The risk or severity of hypertension can be increased when Almotriptan is combined with Lornoxicam.]
[N07XX15, inotersen, Inotersen may decrease the excretion rate of Almotriptan which could result in a higher serum level.]
[M03BA02, carisoprodol, The risk or severity of adverse effects can be increased when Carisoprodol is combined with Almotriptan.]
[R03BB08, revefenacin, Almotriptan may increase the central nervous system depressant (CNS depressant) activities of Revefenacin.]
[L04AA39, emapalumab, The metabolism of Almotriptan can be increased when combined with Emapalumab.]
[L01AD01, carmustine, Carmustine may decrease the excretion rate of Almotriptan which could result in a higher serum level.]
[L01EX13, gilteritinib, The therapeutic efficacy of Almotriptan can be decreased when used in combination with Gilteritinib.]
[L01XJ03, glasdegib, The metabolism of Glasdegib can be decreased when combined with Almotriptan.]
[A06AX05, prucalopride, Almotriptan may decrease the excretion rate of Prucalopride which could result in a higher serum level.]
[C09AA08, cilazapril, Almotriptan may decrease the antihypertensive activities of Cilazapril.]
[B01AC23, cilostazol, Almotriptan may decrease the excretion rate of Cilostazol which could result in a higher serum level.]
[A03FA08, cinitapride, The risk or severity of adverse effects can be increased when Almotriptan is combined with Cinitapride.]
[P02BX04, triclabendazole, The metabolism of Almotriptan can be decreased when combined with Triclabendazole.]
[N06AX27, esketamine, The risk or severity of hypertension can be increased when Esketamine is combined with Almotriptan.]
[L04AA42, siponimod, The risk or severity of hypertension can be increased when Almotriptan is combined with Siponimod.]
[J01FA09, clarithromycin, The metabolism of Almotriptan can be decreased when combined with Clarithromycin.]
[N06BA14, solriamfetol, The risk or severity of hypertension can be increased when Solriamfetol is combined with Almotriptan.]
[N06AX29, brexanolone, The risk or severity of adverse effects can be increased when Almotriptan is combined with Brexanolone.]
[N05BA09, clobazam, The metabolism of Almotriptan can be decreased when combined with Clobazam.]
[N05BA22, cloxazolam, The risk or severity of adverse effects can be increased when Almotriptan is combined with Cloxazolam.]
[C09CA06, candesartan, The metabolism of Almotriptan can be decreased when combined with Candesartan.]
[L04AB01, etanercept, The metabolism of Almotriptan can be increased when combined with Etanercept.]
[L01EM03, alpelisib, The metabolism of Almotriptan can be decreased when combined with Alpelisib.]
[J01DC04, cefaclor, Cefaclor may decrease the excretion rate of Almotriptan which could result in a higher serum level.]
[J01DB05, cefadroxil, Cefadroxil may decrease the excretion rate of Almotriptan which could result in a higher serum level.]
[J01DC03, cefamandole, Cefamandole may decrease the excretion rate of Almotriptan which could result in a higher serum level.]
[J01DB07, cefatrizine, Cefatrizine may decrease the excretion rate of Almotriptan which could result in a higher serum level.]
[J01DB04, cefazolin, Cefazolin may decrease the excretion rate of Almotriptan which could result in a higher serum level.]
[J01DC09, cefmetazole, Cefmetazole may decrease the excretion rate of Almotriptan which could result in a higher serum level.]
[J01DC06, cefonicid, Cefonicid may decrease the excretion rate of Almotriptan which could result in a higher serum level.]
[J01DD12, cefoperazone, Cefoperazone may decrease the excretion rate of Almotriptan which could result in a higher serum level.]
[J01DD01, cefotaxime, Cefotaxime may decrease the excretion rate of Almotriptan which could result in a higher serum level.]
[J01DC05, cefotetan, Cefotetan may decrease the excretion rate of Almotriptan which could result in a higher serum level.]
[N05AA06, cyamemazine, The risk or severity of adverse effects can be increased when Almotriptan is combined with Cyamemazine.]
[J01DC07, cefotiam, Cefotiam may decrease the excretion rate of Almotriptan which could result in a higher serum level.]
[J01DC01, cefoxitin, Cefoxitin may decrease the excretion rate of Almotriptan which could result in a higher serum level.]
[J01DD03, cefsulodin, Cefsulodin may decrease the excretion rate of Almotriptan which could result in a higher serum level.]
[J01DD02, ceftazidime, Ceftazidime may decrease the excretion rate of Almotriptan which could result in a higher serum level.]
[C03BX03, cicletanine, Cicletanine may increase the excretion rate of Almotriptan which could result in a lower serum level and potentially a reduction in efficacy.]
[J01DD07, ceftizoxime, Ceftizoxime may decrease the excretion rate of Almotriptan which could result in a higher serum level.]
[J01DD04, ceftriaxone, Ceftriaxone may decrease the excretion rate of Almotriptan which could result in a higher serum level.]
[S01AA27, cefuroxime, Cefuroxime may decrease the excretion rate of Almotriptan which could result in a higher serum level.]
[M03BX08, cyclobenzaprine, The risk or severity of CNS depression can be increased when Cyclobenzaprine is combined with Almotriptan.]
[L01EJ02, fedratinib, The metabolism of Almotriptan can be decreased when combined with Fedratinib.]
[N07XX11, pitolisant, The serum concentration of Almotriptan can be decreased when it is combined with Pitolisant.]
[N04CX01, istradefylline, The metabolism of Istradefylline can be decreased when combined with Almotriptan.]
[C03AA09, cyclothiazide, Cyclothiazide may increase the excretion rate of Almotriptan which could result in a lower serum level and potentially a reduction in efficacy.]
[G04BE04, yohimbine, The risk or severity of adverse effects can be increased when Almotriptan is combined with Yohimbine.]
[J01XX09, daptomycin, Daptomycin may decrease the excretion rate of Almotriptan which could result in a higher serum level.]
[J01DB01, cephalexin, Cephalexin may decrease the excretion rate of Almotriptan which could result in a higher serum level.]
[J01DB02, cephaloridine, Cefaloridine may decrease the excretion rate of Almotriptan which could result in a higher serum level.]
[J01DB03, cephalothin, Cefalotin may decrease the excretion rate of Almotriptan which could result in a higher serum level.]
[J01DB08, cephapirin, Cefapirin may decrease the excretion rate of Almotriptan which could result in a higher serum level.]
[J01DB09, cephradine, Cefradine may decrease the excretion rate of Almotriptan which could result in a higher serum level.]
[N02CC08, lasmiditan, The risk or severity of serotonin syndrome can be increased when Lasmiditan is combined with Almotriptan.]
[N03AX25, cenobamate, The serum concentration of Almotriptan can be decreased when it is combined with Cenobamate.]
[A16AX16, givosiran, The serum concentration of Almotriptan can be increased when it is combined with Givosiran.]
[M09AX08, golodirsen, Almotriptan may decrease the excretion rate of Golodirsen which could result in a higher serum level.]
[R06AB06, dexbrompheniramine, The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Almotriptan.]
[R06AB02, dexchlorpheniramine, The metabolism of Almotriptan can be decreased when combined with Dexchlorpheniramine.]
[S01XA12, dexpanthenol, Almotriptan may decrease the excretion rate of Dexpanthenol which could result in a higher serum level.]
[N02AX03, dezocine, The risk or severity of adverse effects can be increased when Almotriptan is combined with Dezocine.]
[N05CM21, lemborexant, The risk or severity of adverse effects can be increased when Almotriptan is combined with Lemborexant.]
[N05AD10, lumateperone, The risk or severity of adverse effects can be increased when Almotriptan is combined with Lumateperone.]
[M01AX21, diacetylrhein, The metabolism of Almotriptan can be decreased when combined with Diacerein.]
[H02CA02, osilodrostat, The metabolism of Almotriptan can be decreased when combined with Osilodrostat.]
[J05AE05, amprenavir, The metabolism of Almotriptan can be decreased when combined with Amprenavir.]
[N02CC07, frovatriptan, The risk or severity of adverse effects can be increased when Almotriptan is combined with Frovatriptan.]
[G04CB02, dutasteride, The risk or severity of hypertension can be increased when Almotriptan is combined with Dutasteride.]
[L04AA38, ozanimod, The metabolism of Ozanimod can be decreased when combined with Almotriptan.]
[N05CC04, dichloralphenazone, The risk or severity of adverse effects can be increased when Almotriptan is combined with Dichloralphenazone.]
[L01EE04, selumetinib, The metabolism of Selumetinib can be decreased when combined with Almotriptan.]
[R02AA03, dichlorobenzyl alcohol, Almotriptan may decrease the excretion rate of Dichlorobenzyl alcohol which could result in a higher serum level.]
[G03DB08, dienogest, Almotriptan may decrease the excretion rate of Dienogest which could result in a higher serum level.]
[A07DA04, difenoxin, The risk or severity of adverse effects can be increased when Almotriptan is combined with Difenoxin.]
[N02AA08, dihydrocodeine, The risk or severity of adverse effects can be increased when Almotriptan is combined with Dihydrocodeine.]
[N02CC06, eletriptan, The risk or severity of adverse effects can be increased when Eletriptan is combined with Almotriptan.]
[M01AH02, rofecoxib, The risk or severity of hypertension can be increased when Rofecoxib is combined with Almotriptan.]
[L01XF03, bexarotene, The metabolism of Almotriptan can be decreased when combined with Bexarotene.]
[C08CA16, clevidipine, Almotriptan may decrease the excretion rate of Clevidipine which could result in a higher serum level.]
[C01BD07, dronedarone, The metabolism of Almotriptan can be decreased when combined with Dronedarone.]
[N03AG02, dipropylacetamide, The risk or severity of adverse effects can be increased when Almotriptan is combined with Valpromide.]
[N05BA02, chlordiazepoxide, The risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Almotriptan.]
[C02AA06, methoserpidine, Almotriptan may decrease the antihypertensive activities of Methoserpidine.]
[L01EH03, tucatinib, The metabolism of Tucatinib can be decreased when combined with Almotriptan.]
[A03AA08, dihexyverine, Almotriptan may increase the central nervous system depressant (CNS depressant) activities of Dihexyverine.]
[C01CA14, dopexamine, The risk or severity of hypertension can be increased when Almotriptan is combined with Dopexamine.]
[G04BD09, trospium, Almotriptan may increase the central nervous system depressant (CNS depressant) activities of Trospium.]
[M01AC04, droxicam, The risk or severity of hypertension can be increased when Almotriptan is combined with Droxicam.]
[V08CA05, mangafodipir, Almotriptan may decrease the excretion rate of Mangafodipir which could result in a higher serum level.]
[L01EX22, selpercatinib, The serum concentration of Almotriptan can be increased when it is combined with Selpercatinib.]
[M02AA27, dexketoprofen, The risk or severity of hypertension can be increased when Almotriptan is combined with Dexketoprofen.]
[N05CM02, chlormethiazole, The risk or severity of adverse effects can be increased when Almotriptan is combined with Clomethiazole.]
[M03BB02, chlormezanone, The risk or severity of adverse effects can be increased when Almotriptan is combined with Chlormezanone.]
[R02AD04, dyclonine, The risk or severity of adverse effects can be increased when Dyclonine is combined with Almotriptan.]
[C08CA17, levamlodipine, Almotriptan may decrease the antihypertensive activities of Levamlodipine.]
[P01BB01, proguanil, The metabolism of Almotriptan can be decreased when combined with Proguanil.]
[N05CD14, remimazolam, The risk or severity of adverse effects can be increased when Almotriptan is combined with Remimazolam.]
[L04AC19, satralizumab, The serum concentration of Almotriptan can be decreased when it is combined with Satralizumab.]
[N02AX07, oliceridine, The risk or severity of hypotension, sedation, death, somnolence, and respiratory depression can be increased when Almotriptan is combined with Oliceridine.]
[P01BA01, chloroquine, The metabolism of Almotriptan can be decreased when combined with Chloroquine.]
[L01EX23, pralsetinib, The metabolism of Almotriptan can be decreased when combined with Pralsetinib.]
[C03AA04, chlorothiazide, Chlorothiazide may increase the excretion rate of Almotriptan which could result in a lower serum level and potentially a reduction in efficacy.]
[R06AB04, chlorpheniramine, The risk or severity of adverse effects can be increased when Almotriptan is combined with Chlorpheniramine.]
[N05AA01, chlorpromazine, The metabolism of Almotriptan can be decreased when combined with Chlorpromazine.]
[A10BB02, chlorpropamide, Chlorpropamide may decrease the excretion rate of Almotriptan which could result in a higher serum level.]
[N05AF03, chlorprothixene, Almotriptan may increase the central nervous system depressant (CNS depressant) activities of Chlorprothixene.]
[C03BA04, chlorthalidone, Chlorthalidone may increase the excretion rate of Almotriptan which could result in a lower serum level and potentially a reduction in efficacy.]
[M03BB03, chlorzoxazone, The risk or severity of adverse effects can be increased when Chlorzoxazone is combined with Almotriptan.]
[A11CC05, cholecalciferol, The metabolism of Almotriptan can be decreased when combined with Cholecalciferol.]
[N05BX03, etifoxine, The risk or severity of adverse effects can be increased when Almotriptan is combined with Etifoxine.]
[N02BA07, ethenzamide, The risk or severity of hypertension can be increased when Almotriptan is combined with Ethenzamide.]
[N02BA03, choline salicylate, Almotriptan may decrease the excretion rate of Choline salicylate which could result in a higher serum level.]
[N06BX18, vinpocetine, The risk or severity of adverse effects can be increased when Almotriptan is combined with Vinpocetine.]
[N05BA18, ethyl loflazepate, The risk or severity of adverse effects can be increased when Almotriptan is combined with Ethyl loflazepate.]
[M01AB08, etodolac, The risk or severity of hypertension can be increased when Etodolac is combined with Almotriptan.]
[M02AA06, etofenamate, The risk or severity of hypertension can be increased when Almotriptan is combined with Etofenamate.]
[B06AC06, berotralstat, The metabolism of Almotriptan can be decreased when combined with Berotralstat.]
[A16AX20, lonafarnib, The metabolism of Almotriptan can be decreased when combined with Lonafarnib.]
[M01AX25, chondroitin sulfates, Almotriptan may decrease the excretion rate of Chondroitin sulfate which could result in a higher serum level.]
[L01FX21, naxitamab, The risk or severity of hypertension can be increased when Almotriptan is combined with Naxitamab.]
[P03AX07, abametapir, The serum concentration of Almotriptan can be increased when it is combined with Abametapir.]
[M03BA05, febarbamate, The risk or severity of adverse effects can be increased when Almotriptan is combined with Febarbamate.]
[N03AX10, felbamate, The risk or severity of adverse effects can be increased when Almotriptan is combined with Felbamate.]
[M01AE05, fenbufen, The risk or severity of hypertension can be increased when Almotriptan is combined with Fenbufen.]
[C01CA19, fenoldopam, Almotriptan may decrease the antihypertensive activities of Fenoldopam.]
[N06BA08, fenozolone, The risk or severity of hypertension can be increased when Almotriptan is combined with Fenozolone.]
[G04CB01, finasteride, The risk or severity of hypertension can be increased when Almotriptan is combined with Finasteride.]
[J01DD15, cefdinir, Cefdinir may decrease the excretion rate of Almotriptan which could result in a higher serum level.]
[N02BG07, flupirtine, Almotriptan may decrease the excretion rate of Flupirtine which could result in a higher serum level.]
[R03CC15, formoterol, The risk or severity of hypertension can be increased when Almotriptan is combined with Formoterol.]
[N01AB05, trichloroethylene, The risk or severity of adverse effects can be increased when Almotriptan is combined with Trichloroethylene.]
[L03AB10, peginterferon alfa-2b, The metabolism of Almotriptan can be decreased when combined with Peginterferon alfa-2b.]
[H04AA02, dasiglucagon, Almotriptan may decrease the antihypertensive activities of Dasiglucagon.]
[A02BA01, cimetidine, The metabolism of Almotriptan can be decreased when combined with Cimetidine.]
[N02BF01, gabapentin, The risk or severity of adverse effects can be increased when Almotriptan is combined with Gabapentin.]
[V08CA04, gadoteridol, Gadoteridol may decrease the excretion rate of Almotriptan which could result in a higher serum level.]
[N07CA02, cinnarizine, The metabolism of Almotriptan can be decreased when combined with Cinnarizine.]
[L01XX73, sotorasib, The serum concentration of Almotriptan can be decreased when it is combined with Sotorasib.]
[S03AA07, ciprofloxacin, The metabolism of Almotriptan can be decreased when combined with Ciprofloxacin.]
[L01XA01, cisplatin, Almotriptan may decrease the excretion rate of Cisplatin which could result in a higher serum level.]
[N06AB04, citalopram, The risk or severity of adverse effects can be increased when Almotriptan is combined with Citalopram.]
[C03DA05, finerenone, Finerenone may increase the excretion rate of Almotriptan which could result in a lower serum level and potentially a reduction in efficacy.]
[P01CA03, fexinidazole, The metabolism of Fexinidazole can be decreased when combined with Almotriptan.]
[V09AB03, ioflupane I-123, Almotriptan may decrease the excretion rate of Ioflupane I-123 which could result in a higher serum level.]
[V09AA01, technetium Tc 99m exametazime, Almotriptan may decrease the excretion rate of Technetium Tc-99m exametazime which could result in a higher serum level.]
[V09AX06, florbetaben f-18, Almotriptan may decrease the excretion rate of Florbetaben (18F) which could result in a higher serum level.]
[R06AA04, clemastine, The risk or severity of adverse effects can be increased when Clemastine is combined with Almotriptan.]
[R03CC13, clenbuterol, The risk or severity of hypertension can be increased when Almotriptan is combined with Clenbuterol.]
[N06AX25, St. John's wort extract, The metabolism of Almotriptan can be increased when combined with St. John's Wort.]
[L03AB15, ropeginterferon alfa-2b, The risk or severity of neuropsychiatric effects can be increased when Ropeginterferon alfa-2b is combined with Almotriptan.]
[B06AX04, mitapivat, The metabolism of Almotriptan can be increased when combined with Mitapivat.]
[N01BB10, levobupivacaine, The risk or severity of adverse effects can be increased when Almotriptan is combined with Levobupivacaine.]
[N06AA04, clomipramine, The metabolism of Clomipramine can be decreased when combined with Almotriptan.]
[N03AE01, clonazepam, The risk or severity of adverse effects can be increased when Almotriptan is combined with Clonazepam.]
[S01EA04, clonidine, The risk or severity of sedation can be increased when Clonidine is combined with Almotriptan.]
[C01EB24, mavacamten, The serum concentration of Almotriptan can be decreased when it is combined with Mavacamten.]
[J05AH02, oseltamivir, Oseltamivir may decrease the excretion rate of Almotriptan which could result in a higher serum level.]
[C03BA03, clopamide, Clopamide may increase the excretion rate of Almotriptan which could result in a lower serum level and potentially a reduction in efficacy.]
[N05AH06, clothiapine, The risk or severity of adverse effects can be increased when Almotriptan is combined with Clothiapine.]
[H01CC04, linzagolix, The serum concentration of Almotriptan can be increased when it is combined with Linzagolix.]
[N05BA21, clotiazepam, The risk or severity of adverse effects can be increased when Almotriptan is combined with Clotiazepam.]
[A04AA01, ondansetron, The risk or severity of adverse effects can be increased when Ondansetron is combined with Almotriptan.]
[A04AA02, granisetron, The risk or severity of adverse effects can be increased when Granisetron is combined with Almotriptan.]
[N05AH02, clozapine, The metabolism of Almotriptan can be decreased when combined with Clozapine.]
[J01GB12, arbekacin, Almotriptan may decrease the excretion rate of Arbekacin which could result in a higher serum level.]
[N05BA13, halazepam, The risk or severity of adverse effects can be increased when Halazepam is combined with Almotriptan.]
[H01AC08, somatrogon, The metabolism of Almotriptan can be increased when combined with Somatrogon.]
[S02DA02, cocaine, Almotriptan may increase the central nervous system depressant (CNS depressant) activities of Cocaine.]
[C02KB01, metyrosine, Almotriptan may increase the sedative activities of Metyrosine.]
[L04AC21, bimekizumab, The metabolism of Almotriptan can be increased when combined with Bimekizumab.]
[M01AX13, proquazone, The risk or severity of hypertension can be increased when Almotriptan is combined with Proquazone.]
[R05DA04, codeine, The risk or severity of adverse effects can be increased when Codeine is combined with Almotriptan.]
[M03AC05, hexafluorenium, The risk or severity of adverse effects can be increased when Almotriptan is combined with Hexafluronium.]
[M04AC01, colchicine, Almotriptan may decrease the excretion rate of Colchicine which could result in a higher serum level.]
[A03AB10, hexocyclium, Almotriptan may increase the central nervous system depressant (CNS depressant) activities of Hexocyclium.]
[A03BB06, homatropine methylbromide, Almotriptan may increase the central nervous system depressant (CNS depressant) activities of Homatropine methylbromide.]
[J01XB01, colistin, Almotriptan may decrease the excretion rate of Colistin which could result in a higher serum level.]
[J01DE02, cefpirome, Cefpirome may decrease the excretion rate of Almotriptan which could result in a higher serum level.]
[N01AB07, desflurane, The risk or severity of adverse effects can be increased when Almotriptan is combined with Desflurane.]
[A04AA03, tropisetron, The risk or severity of adverse effects can be increased when Almotriptan is combined with Tropisetron.]
[C04AX28, ifenprodil, The risk or severity of adverse effects can be increased when Almotriptan is combined with Ifenprodil.]
[A10BX03, nateglinide, Nateglinide may decrease the excretion rate of Almotriptan which could result in a higher serum level.]
[N02BA16, imidazole-2-hydroxybenzoate, The risk or severity of hypertension can be increased when Almotriptan is combined with Imidazole salicylate.]
[J01FA15, telithromycin, The metabolism of Almotriptan can be decreased when combined with Telithromycin.]
[R03BA08, ciclesonide, The metabolism of Ciclesonide can be decreased when combined with Almotriptan.]
[B01AC10, indobufen, The risk or severity of hypertension can be increased when Almotriptan is combined with Indobufen.]
[R06AX27, desloratadine, The risk or severity of adverse effects can be increased when Almotriptan is combined with Desloratadine.]
[J05AB14, valganciclovir, Almotriptan may decrease the excretion rate of Valganciclovir which could result in a higher serum level.]
[C05BB03, invert sugar, Almotriptan may decrease the excretion rate of Invert sugar which could result in a higher serum level.]
[V08AB09, iodixanol, Almotriptan may decrease the excretion rate of Iodixanol which could result in a higher serum level.]
[V08AB05, iopromide, Almotriptan may decrease the excretion rate of Iopromide which could result in a higher serum level.]
[V08AB07, ioversol, Almotriptan may decrease the excretion rate of Ioversol which could result in a higher serum level.]
[V08AB12, ioxilan, Almotriptan may decrease the excretion rate of Ioxilan which could result in a higher serum level.]
[M01AH03, valdecoxib, The risk or severity of hypertension can be increased when Valdecoxib is combined with Almotriptan.]
[A03AX10, isometheptene, The risk or severity of hypertension can be increased when Almotriptan is combined with Isometheptene.]
[S01AA13, fusidic acid, The metabolism of Almotriptan can be decreased when combined with Fusidic acid.]
[N07XX04, sodium oxybate, Almotriptan may increase the central nervous system depressant (CNS depressant) activities of Sodium oxybate.]
[S02BA08, fluocinolone acetonide, Fluocinolone acetonide may decrease the excretion rate of Almotriptan which could result in a higher serum level.]
[M01AG01, mefenamic acid, The risk or severity of hypertension can be increased when Mefenamic acid is combined with Almotriptan.]
[M01AH04, parecoxib, The risk or severity of hypertension can be increased when Almotriptan is combined with Parecoxib.]
[J02AC02, itraconazole, The metabolism of Almotriptan can be decreased when combined with Itraconazole.]
[S01AD03, acyclovir, Acyclovir may decrease the excretion rate of Almotriptan which could result in a higher serum level.]
[N05BA10, ketazolam, The risk or severity of adverse effects can be increased when Almotriptan is combined with Ketazolam.]
[M01AA06, kebuzone, The risk or severity of hypertension can be increased when Almotriptan is combined with Kebuzone.]
[L01EA01, imatinib, The serum concentration of Almotriptan can be increased when it is combined with Imatinib.]
[J02AC04, posaconazole, The metabolism of Almotriptan can be decreased when combined with Posaconazole.]
[C08CA09, lacidipine, Almotriptan may decrease the antihypertensive activities of Lacidipine.]
[N03AX09, lamotrigine, Almotriptan may increase the central nervous system depressant (CNS depressant) activities of Lamotrigine.]
[N07BC04, lofexidine, The therapeutic efficacy of Almotriptan can be increased when used in combination with Lofexidine.]
[M01AB09, lonazolac, The risk or severity of hypertension can be increased when Almotriptan is combined with Lonazolac.]
[R06AX13, loratadine, The metabolism of Almotriptan can be decreased when combined with Loratadine.]
[N05CD06, lormetazepam, The risk or severity of adverse effects can be increased when Almotriptan is combined with Lormetazepam.]
[M02AA31, loxoprofen, The risk or severity of hypertension can be increased when Almotriptan is combined with Loxoprofen.]
[J01DC08, loracarbef, Loracarbef may decrease the excretion rate of Almotriptan which could result in a higher serum level.]
[C09AA03, lisinopril, Almotriptan may decrease the antihypertensive activities of Lisinopril.]
[A06AD01, magnesium carbonate, Almotriptan may decrease the excretion rate of Magnesium carbonate which could result in a higher serum level.]
[C08CA11, manidipine, The metabolism of Almotriptan can be decreased when combined with Manidipine.]
[A03AA04, mebeverine, Almotriptan may increase the central nervous system depressant (CNS depressant) activities of Mebeverine.]
[N06AX13, medifoxamine, The risk or severity of adverse effects can be increased when Almotriptan is combined with Medifoxamine.]
[A08AA09, mefenorex, The risk or severity of hypertension can be increased when Almotriptan is combined with Mefenorex.]
[C07AA14, mepindolol, The metabolism of Mepindolol can be decreased when combined with Almotriptan.]
[R06AD07, mequitazine, The metabolism of Mequitazine can be decreased when combined with Almotriptan.]
[J01DH02, meropenem, Meropenem may decrease the excretion rate of Almotriptan which could result in a higher serum level.]
[N04AA03, methixene, Almotriptan may increase the central nervous system depressant (CNS depressant) activities of Metixene.]
[R03CB02, methoxyphenamine, The risk or severity of serotonin syndrome can be increased when Almotriptan is combined with Methoxyphenamine.]
[R06AE03, cyclizine, The risk or severity of adverse effects can be increased when Almotriptan is combined with Cyclizine.]
[N05CA10, cyclobarbital, The risk or severity of adverse effects can be increased when Almotriptan is combined with Cyclobarbital.]
[C03DA04, eplerenone, Eplerenone may increase the excretion rate of Almotriptan which could result in a lower serum level and potentially a reduction in efficacy.]
[N05AD03, metylperon, The risk or severity of adverse effects can be increased when Almotriptan is combined with Melperone.]
[C03AA07, cyclopenthiazide, Cyclopenthiazide may increase the excretion rate of Almotriptan which could result in a lower serum level and potentially a reduction in efficacy.]
[J05AF07, tenofovir disoproxil, Tenofovir disoproxil may decrease the excretion rate of Almotriptan which could result in a higher serum level.]
[L01AA01, cyclophosphamide, The metabolism of Almotriptan can be increased when combined with Cyclophosphamide.]
[N06AX07, minaprine, The metabolism of Almotriptan can be decreased when combined with Minaprine.]
[S01XA18, cyclosporine, The metabolism of Almotriptan can be decreased when combined with Cyclosporine.]
[N06AG02, moclobemide, The metabolism of Almotriptan can be decreased when combined with Moclobemide.]
[R06AX02, cyproheptadine, Almotriptan may increase the central nervous system depressant (CNS depressant) activities of Cyproheptadine.]
[C09AA13, moexipril, Almotriptan may decrease the antihypertensive activities of Moexipril.]
[M02AA02, mofebutazone, The risk or severity of hypertension can be increased when Almotriptan is combined with Mofebutazone.]
[M01AX22, morniflumate, The risk or severity of hypertension can be increased when Almotriptan is combined with Morniflumate.]
[C03XA02, conivaptan, The metabolism of Almotriptan can be decreased when combined with Conivaptan.]
[C02AC05, moxonidine, Almotriptan may decrease the antihypertensive activities of Moxonidine.]
[M01AH05, etoricoxib, The risk or severity of hypertension can be increased when Almotriptan is combined with Etoricoxib.]
[L01AX04, dacarbazine, Dacarbazine may decrease the excretion rate of Almotriptan which could result in a higher serum level.]
[G03XA01, danazol, The metabolism of Almotriptan can be decreased when combined with Danazol.]
[M03CA01, dantrolene, The risk or severity of adverse effects can be increased when Almotriptan is combined with Dantrolene.]
[J04BA02, dapsone, The metabolism of Almotriptan can be decreased when combined with Dapsone.]
[N06BX04, deanol, The risk or severity of adverse effects can be increased when Almotriptan is combined with Deanol.]
[C02CC04, debrisoquin, Almotriptan may decrease the antihypertensive activities of Debrisoquine.]
[A04AD11, nabilone, Nabilone may increase the central nervous system depressant (CNS depressant) activities of Almotriptan.]
[M01AX01, nabumetone, The risk or severity of hypertension can be increased when Nabumetone is combined with Almotriptan.]
[N07BB05, nalmefene, Almotriptan may decrease the excretion rate of Nalmefene which could result in a higher serum level.]
[N05BA16, nordazepam, The risk or severity of adverse effects can be increased when Almotriptan is combined with Nordazepam.]
[C07AB12, nebivolol, Almotriptan may decrease the antihypertensive activities of Nebivolol.]
[S01GX04, nedocromil, Nedocromil may decrease the excretion rate of Almotriptan which could result in a higher serum level.]
[N06AX06, nefazodone, The metabolism of Almotriptan can be decreased when combined with Nefazodone.]
[N05CM16, niaprazine, The risk or severity of adverse effects can be increased when Almotriptan is combined with Niaprazine.]
[C01DX16, nicorandil, Almotriptan may decrease the antihypertensive activities of Nicorandil.]
[L02BB02, nilutamide, The metabolism of Almotriptan can be decreased when combined with Nilutamide.]
[N03AG06, tiagabine, The risk or severity of adverse effects can be increased when Tiagabine is combined with Almotriptan.]
[C01CA23, theodrenaline, The risk or severity of hypertension can be increased when Almotriptan is combined with Theodrenaline.]
[M03AC11, cisatracurium, The risk or severity of adverse effects can be increased when Cisatracurium is combined with Almotriptan.]
[C01CA05, norfenefrine, The risk or severity of hypertension can be increased when Almotriptan is combined with Norfenefrine.]
[R05DA06, normethadone, The risk or severity of adverse effects can be increased when Almotriptan is combined with Normethadone.]
[B01AX05, fondaparinux, Fondaparinux may decrease the excretion rate of Almotriptan which could result in a higher serum level.]
[N06AB10, escitalopram, The risk or severity of serotonin syndrome can be increased when Almotriptan is combined with Escitalopram.]
[G04BD08, solifenacin, Almotriptan may increase the central nervous system depressant (CNS depressant) activities of Solifenacin.]
[A07EC03, olsalazine, The risk or severity of hypertension can be increased when Almotriptan is combined with Olsalazine.]
[N06AA01, desipramine, The metabolism of Almotriptan can be decreased when combined with Desipramine.]
[H01BA02, desmopressin, The risk or severity of hypertension can be increased when Desmopressin is combined with Almotriptan.]
[J01DH03, ertapenem, Ertapenem may decrease the excretion rate of Almotriptan which could result in a higher serum level.]
[C09XA02, aliskiren, Almotriptan may decrease the antihypertensive activities of Aliskiren.]
[M01AE12, oxaprozin, The risk or severity of hypertension can be increased when Almotriptan is combined with Oxaprozin.]
[N03AF02, oxcarbazepine, The risk or severity of adverse effects can be increased when Oxcarbazepine is combined with Almotriptan.]
[S03BA01, dexamethasone, The metabolism of Almotriptan can be increased when combined with Dexamethasone.]
[N06BX07, oxiracetam, The risk or severity of adverse effects can be increased when Almotriptan is combined with Oxiracetam.]
[N04AA08, dexetimide, Almotriptan may increase the central nervous system depressant (CNS depressant) activities of Dexetimide.]
[G04BD04, oxybutynin, Almotriptan may increase the central nervous system depressant (CNS depressant) activities of Oxybutynin.]
[A08AA04, dexfenfluramine, The risk or severity of serotonin syndrome can be increased when Almotriptan is combined with Dexfenfluramine.]
[A03AA01, oxyphencyclimine, Almotriptan may increase the central nervous system depressant (CNS depressant) activities of Oxyphencyclimine.]
[L04AB04, adalimumab, The metabolism of Almotriptan can be increased when combined with Adalimumab.]
[L01EB01, gefitinib, The metabolism of Almotriptan can be decreased when combined with Gefitinib.]
[N06BA02, dextroamphetamine, The risk or severity of serotonin syndrome can be increased when Amphetamine is combined with Almotriptan.]
[R05DA09, dextromethorphan, The risk or severity of adverse effects can be increased when Dextromethorphan is combined with Almotriptan.]
[N03AC01, paramethadione, The risk or severity of adverse effects can be increased when Paramethadione is combined with Almotriptan.]
[N02AC01, dextromoramide, The risk or severity of adverse effects can be increased when Almotriptan is combined with Dextromoramide.]
[N06AB05, paroxetine, The risk or severity of serotonin syndrome can be increased when Paroxetine is combined with Almotriptan.]
[B01AC04, clopidogrel, The metabolism of Almotriptan can be decreased when combined with Clopidogrel.]
[N07BC06, heroin, The risk or severity of adverse effects can be increased when Almotriptan is combined with Diamorphine.]
[C01DA05, pentaerythritol tetranitrate, Almotriptan may decrease the excretion rate of Pentaerythritol tetranitrate which could result in a higher serum level.]
[P03AC04, permethrin, Almotriptan may decrease the excretion rate of Permethrin which could result in a higher serum level.]
[N05BA01, diazepam, The risk or severity of adverse effects can be increased when Diazepam is combined with Almotriptan.]
[N03AX07, phenacemide, The risk or severity of adverse effects can be increased when Almotriptan is combined with Phenacemide.]
[V03AH01, diazoxide, Almotriptan may decrease the antihypertensive activities of Diazoxide.]
[N03AD02, phensuximide, The risk or severity of adverse effects can be increased when Phensuximide is combined with Almotriptan.]
[N06AA08, dibenzepin, The risk or severity of adverse effects can be increased when Almotriptan is combined with Dibenzepin.]
[S02DA04, dibucaine, The risk or severity of adverse effects can be increased when Cinchocaine is combined with Almotriptan.]
[R05DA08, pholcodine, Almotriptan may decrease the excretion rate of Pholcodine which could result in a higher serum level.]
[S01EC02, dichlorphenamide, Diclofenamide may increase the excretion rate of Almotriptan which could result in a lower serum level and potentially a reduction in efficacy.]
[S01BC03, diclofenac, The metabolism of Almotriptan can be decreased when combined with Diclofenac.]
[J05AD01, foscarnet, Foscarnet may decrease the excretion rate of Almotriptan which could result in a higher serum level.]
[A03AA07, dicyclomine, Almotriptan may increase the central nervous system depressant (CNS depressant) activities of Dicyclomine.]
[J05AF02, didanosine, Didanosine may decrease the excretion rate of Almotriptan which could result in a higher serum level.]
[C02DG01, pinacidil, Almotriptan may decrease the antihypertensive activities of Pinacidil.]
[A10BG03, pioglitazone, The metabolism of Almotriptan can be decreased when combined with Pioglitazone.]
[N05AD05, pipamperone, The risk or severity of adverse effects can be increased when Almotriptan is combined with Pipamperone.]
[A03AB14, pipenzolate, Almotriptan may increase the central nervous system depressant (CNS depressant) activities of Pipenzolate.]
[L01EB02, erlotinib, The metabolism of Erlotinib can be decreased when combined with Almotriptan.]
[R03CC07, pirbuterol, The risk or severity of hypertension can be increased when Almotriptan is combined with Pirbuterol.]
[C03CA03, piretanide, Piretanide may increase the excretion rate of Almotriptan which could result in a lower serum level and potentially a reduction in efficacy.]
[A08AA03, diethylpropion, The risk or severity of adverse effects can be increased when Almotriptan is combined with Diethylpropion.]
[L02AA01, diethylstilbestrol, The metabolism of Almotriptan can be decreased when combined with Diethylstilbestrol.]
[C08CA03, isradipine, The metabolism of Almotriptan can be decreased when combined with Isradipine.]
[D07XC04, diflucortolone, Almotriptan may decrease the excretion rate of Difluocortolone which could result in a higher serum level.]
[A03AB11, poldine, Almotriptan may increase the central nervous system depressant (CNS depressant) activities of Poldine.]
[N02BA11, diflunisal, The risk or severity of hypertension can be increased when Diflunisal is combined with Almotriptan.]
[C01AA05, digoxin, Almotriptan may decrease the excretion rate of Digoxin which could result in a higher serum level.]
[C02DB01, dihydralazine, Almotriptan may decrease the antihypertensive activities of Dihydralazine.]
[C04AE04, dihydroergocristine, Dihydroergocristine may increase the vasoconstricting activities of Almotriptan.]
[N02CA01, dihydroergotamine, Dihydroergotamine may increase the vasoconstricting activities of Almotriptan.]
[N02AA03, hydromorphone, The risk or severity of adverse effects can be increased when Hydromorphone is combined with Almotriptan.]
[L04AX04, lenalidomide, Lenalidomide may decrease the excretion rate of Almotriptan which could result in a higher serum level.]
[J05AE08, atazanavir, The metabolism of Almotriptan can be decreased when combined with Atazanavir.]
[B01AC21, treprostinil, The metabolism of Almotriptan can be decreased when combined with Treprostinil.]
[H03BC01, potassium perchlorate, Almotriptan may decrease the excretion rate of Potassium perchlorate which could result in a higher serum level.]
[V03AB04, pralidoxime, Pralidoxime may decrease the excretion rate of Almotriptan which could result in a higher serum level.]
[D04AB07, pramoxine, The risk or severity of adverse effects can be increased when Almotriptan is combined with Pramocaine.]
[C08DB01, diltiazem, The metabolism of Almotriptan can be decreased when combined with Diltiazem.]
[R06AA11, dimenhydrinate, The risk or severity of adverse effects can be increased when Almotriptan is combined with Dimenhydrinate.]
[V03AB09, dimercaprol, Almotriptan may decrease the excretion rate of Dimercaprol which could result in a higher serum level.]
[M03BX03, pridinol, The risk or severity of adverse effects can be increased when Almotriptan is combined with Pridinol.]
[R06AB03, dimethindene, Almotriptan may increase the central nervous system depressant (CNS depressant) activities of Dimetindene.]
[R03CC08, procaterol, The risk or severity of hypertension can be increased when Almotriptan is combined with Procaterol.]
[M02AX03, dimethyl sulfoxide, The metabolism of Almotriptan can be decreased when combined with Dimethyl sulfoxide.]
[N03AG05, progabide, The risk or severity of adverse effects can be increased when Progabide is combined with Almotriptan.]
[N02BB04, propyphenazone, The risk or severity of hypertension can be increased when Almotriptan is combined with Propyphenazone.]
[M01AB14, proglumetacin, The risk or severity of hypertension can be increased when Almotriptan is combined with Proglumetacin.]
[R06AA02, diphenhydramine, Almotriptan may increase the central nervous system depressant (CNS depressant) activities of Diphenhydramine.]
[A07DA01, diphenoxylate, The risk or severity of adverse effects can be increased when Almotriptan is combined with Diphenoxylate.]
[N05CD10, quazepam, The risk or severity of adverse effects can be increased when Almotriptan is combined with Quazepam.]
[C09AA06, quinapril, Almotriptan may decrease the antihypertensive activities of Quinapril.]
[N06BA11, dexmethylphenidate, The risk or severity of adverse effects can be increased when Almotriptan is combined with Dexmethylphenidate.]
[N06AA23, quinupramine, The risk or severity of adverse effects can be increased when Almotriptan is combined with Quinupramine.]
[A03FA02, cisapride, The metabolism of Almotriptan can be decreased when combined with Cisapride.]
[C09AA05, ramipril, Almotriptan may decrease the antihypertensive activities of Ramipril.]
[N05AL04, remoxipride, The risk or severity of adverse effects can be increased when Almotriptan is combined with Remoxipride.]
[R03CC14, reproterol, The risk or severity of hypertension can be increased when Almotriptan is combined with Reproterol.]
[S01AX06, resorcinol, Almotriptan may decrease the excretion rate of Resorcinol which could result in a higher serum level.]
[C01BA03, disopyramide, Almotriptan may increase the central nervous system depressant (CNS depressant) activities of Disopyramide.]
[S02AA12, rifamycin SV, The metabolism of Almotriptan can be increased when combined with Rifamycin.]
[J04AB05, rifapentine, The metabolism of Almotriptan can be increased when combined with Rifapentine.]
[N07XX02, riluzole, The risk or severity of adverse effects can be increased when Riluzole is combined with Almotriptan.]
[N05AX08, risperidone, The risk or severity of adverse effects can be increased when Almotriptan is combined with Risperidone.]
[R06AE09, levocetirizine, The risk or severity of adverse effects can be increased when Almotriptan is combined with Levocetirizine.]
[N01BB09, ropivacaine, The risk or severity of adverse effects can be increased when Ropivacaine is combined with Almotriptan.]
[A04AD12, aprepitant, The metabolism of Almotriptan can be decreased when combined with Aprepitant.]
[C03XA01, tolvaptan, Tolvaptan may increase the excretion rate of Almotriptan which could result in a lower serum level and potentially a reduction in efficacy.]
[L01XG01, bortezomib, The metabolism of Almotriptan can be decreased when combined with Bortezomib.]
[G04BE08, tadalafil, Almotriptan may decrease the antihypertensive activities of Tadalafil.]
[S01BC05, ketorolac, The metabolism of Almotriptan can be decreased when combined with Ketorolac.]
[C02KX02, ambrisentan, Almotriptan may decrease the antihypertensive activities of Ambrisentan.]
[C01EB18, ranolazine, The serum concentration of Almotriptan can be increased when it is combined with Ranolazine.]
[N02BA06, salsalate, The risk or severity of hypertension can be increased when Almotriptan is combined with Salsalate.]
[R03AC12, salmeterol, The metabolism of Almotriptan can be decreased when combined with Salmeterol.]
[H05BA01, salmon calcitonin, Salmon calcitonin may decrease the excretion rate of Almotriptan which could result in a higher serum level.]
[C01CA07, dobutamine, The risk or severity of hypertension can be increased when Dobutamine is combined with Almotriptan.]
[A03FA03, domperidone, The metabolism of Domperidone can be decreased when combined with Almotriptan.]
[C01CA04, dopamine, The risk or severity of hypertension can be increased when Almotriptan is combined with Dopamine.]
[N06AA16, dothiepin, The metabolism of Almotriptan can be decreased when combined with Dosulepin.]
[R07AB01, doxapram, The risk or severity of hypertension can be increased when Doxapram is combined with Almotriptan.]
[N06AA12, doxepin, Almotriptan may increase the central nervous system depressant (CNS depressant) activities of Doxepin.]
[L01DB01, doxorubicin, The metabolism of Almotriptan can be decreased when combined with Doxorubicin.]
[J01AA02, doxycycline, Doxycycline may decrease the excretion rate of Almotriptan which could result in a higher serum level.]
[R06AA09, doxylamine, Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Almotriptan.]
[N06AB06, sertraline, The risk or severity of adverse effects can be increased when Almotriptan is combined with Sertraline.]
[N01AB08, sevoflurane, The risk or severity of adverse effects can be increased when Almotriptan is combined with Sevoflurane.]
[N05AD08, droperidol, Droperidol may increase the central nervous system depressant (CNS depressant) activities of Almotriptan.]
[A08AA10, sibutramine, The risk or severity of adverse effects can be increased when Almotriptan is combined with Sibutramine.]
[C10AA01, simvastatin, The metabolism of Almotriptan can be decreased when combined with Simvastatin.]
[A12CA02, sodium sulfate, Almotriptan may decrease the excretion rate of Sodium sulfate which could result in a higher serum level.]
[C09AA11, spirapril, Almotriptan may decrease the antihypertensive activities of Spirapril.]
[R03DA01, dyphylline, Dyphylline may decrease the excretion rate of Almotriptan which could result in a higher serum level.]
[N05AL02, sultopride, The risk or severity of adverse effects can be increased when Almotriptan is combined with Sultopride.]
[N02CC01, sumatriptan, The risk or severity of adverse effects can be increased when Sumatriptan is combined with Almotriptan.]
[V04CX07, edrophonium, Almotriptan may decrease the excretion rate of Edrophonium which could result in a higher serum level.]
[C07AB13, talinolol, Almotriptan may decrease the antihypertensive activities of Talinolol.]
[L01AX03, temozolomide, Temozolomide may decrease the excretion rate of Almotriptan which could result in a higher serum level.]
[M01AC02, tenoxicam, The risk or severity of hypertension can be increased when Tenoxicam is combined with Almotriptan.]
[G04CA03, terazosin, Almotriptan may decrease the antihypertensive activities of Terazosin.]
[D01BA02, terbinafine, The metabolism of Almotriptan can be decreased when combined with Terbinafine.]
[C07AA16, tertatolol, The metabolism of Tertatolol can be decreased when combined with Almotriptan.]
[S01GA02, tetrahydrozoline, The risk or severity of hypertension can be increased when Almotriptan is combined with Tetryzoline.]
[M03BX07, tetrazepam, The risk or severity of adverse effects can be increased when Almotriptan is combined with Tetrazepam.]
[M03BX05, thiocolchicoside, The risk or severity of adverse effects can be increased when Almotriptan is combined with Thiocolchicoside.]
[N05AB05, thiopropazate, The risk or severity of adverse effects can be increased when Almotriptan is combined with Thiopropazate.]
[G04BD01, emepronium, Almotriptan may increase the central nervous system depressant (CNS depressant) activities of Emepronium.]
[N06AX14, tianeptine, The risk or severity of adverse effects can be increased when Almotriptan is combined with Tianeptine.]
[C09AA02, enalapril, Almotriptan may decrease the antihypertensive activities of Enalapril.]
[N05BA23, tofisopam, The risk or severity of adverse effects can be increased when Almotriptan is combined with Tofisopam.]
[M01AG02, tolfenamic acid, The risk or severity of hypertension can be increased when Almotriptan is combined with Tolfenamic acid.]
[N06AG03, toloxatone, The metabolism of Almotriptan can be decreased when combined with Toloxatone.]
[N06BA09, atomoxetine, The risk or severity of hypertension can be increased when Atomoxetine is combined with Almotriptan.]
[N03AX11, topiramate, The risk or severity of adverse effects can be increased when Topiramate is combined with Almotriptan.]
[C03CA04, torsemide, Torasemide may increase the excretion rate of Almotriptan which could result in a lower serum level and potentially a reduction in efficacy.]
[R01AA09, tramazoline, The risk or severity of hypertension can be increased when Almotriptan is combined with Tramazoline.]
[C09AA10, trandolapril, Almotriptan may decrease the antihypertensive activities of Trandolapril.]
[N05CD11, triazulenone, The risk or severity of adverse effects can be increased when Almotriptan is combined with Loprazolam.]
[N05CM07, triclofos, The risk or severity of adverse effects can be increased when Almotriptan is combined with Triclofos.]
[A03AB08, tridihexethyl, Almotriptan may increase the central nervous system depressant (CNS depressant) activities of Tridihexethyl.]
[R06AA10, trimethobenzamide, The risk or severity of adverse effects can be increased when Trimethobenzamide is combined with Almotriptan.]
[N04AA12, tropatepine, Almotriptan may increase the central nervous system depressant (CNS depressant) activities of Tropatepine.]
[R03CC11, tulobuterol, The risk or severity of hypertension can be increased when Almotriptan is combined with Tulobuterol.]
[N01AB04, enflurane, The risk or severity of adverse effects can be increased when Enflurane is combined with Almotriptan.]
[C02CA06, urapidil, The risk or severity of adverse effects can be increased when Almotriptan is combined with Urapidil.]
[N05AL06, veralipride, The risk or severity of adverse effects can be increased when Almotriptan is combined with Veralipride.]
[L01CA04, vinorelbine, The metabolism of Almotriptan can be decreased when combined with Vinorelbine.]
[S01FB02, ephedrine, The risk or severity of hypertension can be increased when Almotriptan is combined with Ephedrine.]
[S01GX10, epinastine, The risk or severity of adverse effects can be increased when Epinastine is combined with Almotriptan.]
[N06AX16, venlafaxine, The risk or severity of serotonin syndrome can be increased when Almotriptan is combined with Venlafaxine.]
[C01CX07, xamoterol, The risk or severity of hypertension can be increased when Almotriptan is combined with Xamoterol.]
[S01GA03, xylometazoline, The risk or severity of hypertension can be increased when Almotriptan is combined with Xylometazoline.]
[C08CA12, mepirodipine, The metabolism of Almotriptan can be decreased when combined with Barnidipine.]
[S01EA01, epinephrine, The risk or severity of hypertension can be increased when Epinephrine is combined with Almotriptan.]
[C09AA15, zofenopril, Almotriptan may decrease the antihypertensive activities of Zofenopril.]
[N05CF02, zolpidem, Almotriptan may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.]
[M01AB04, zomepirac, The risk or severity of hypertension can be increased when Almotriptan is combined with Zomepirac.]
[N03AX15, zonisamide, The metabolism of Almotriptan can be decreased when combined with Zonisamide.]
[N05CF01, zopiclone, The risk or severity of adverse effects can be increased when Almotriptan is combined with Zopiclone.]
[N05AX11, zotepine, The risk or severity of adverse effects can be increased when Almotriptan is combined with Zotepine.]
[L01XA02, carboplatin, Carboplatin may decrease the excretion rate of Almotriptan which could result in a higher serum level.]
[C02AC02, guanfacine, The risk or severity of adverse effects can be increased when Almotriptan is combined with Guanfacine.]
[C01BG01, moricizine, The risk or severity of adverse effects can be increased when Almotriptan is combined with Moricizine.]
[G02AB03, ergonovine, Ergometrine may increase the vasoconstricting activities of Almotriptan.]
[C04AE01, ergoloid mesylates, USP, Ergoloid mesylate may increase the vasoconstricting activities of Almotriptan.]
[N02CA02, ergotamine, The metabolism of Almotriptan can be decreased when combined with Ergotamine.]
[L03AX05, pidotimod, Almotriptan may decrease the excretion rate of Pidotimod which could result in a higher serum level.]
[S01AA17, erythromycin, The metabolism of Almotriptan can be decreased when combined with Erythromycin.]
[N05CD04, estazolam, The risk or severity of adverse effects can be increased when Almotriptan is combined with Estazolam.]
[A02BC02, pantoprazole, Pantoprazole may decrease the excretion rate of Almotriptan which could result in a higher serum level.]
[H05BX01, cinacalcet, The metabolism of Almotriptan can be decreased when combined with Cinacalcet.]
[G03CA03, estradiol, The metabolism of Almotriptan can be decreased when combined with Estradiol.]
[G03CA57, estrogens, conjugated (USP), Conjugated estrogens may decrease the excretion rate of Almotriptan which could result in a higher serum level.]
[J04AK02, ethambutol, Ethambutol may decrease the excretion rate of Almotriptan which could result in a higher serum level.]
[R03BA09, fluticasone furoate, The metabolism of Almotriptan can be decreased when combined with Fluticasone furoate.]
[R03BA05, fluticasone, The metabolism of Almotriptan can be decreased when combined with Fluticasone.]
[C10AA04, fluvastatin, The metabolism of Almotriptan can be decreased when combined with Fluvastatin.]
[V08CA03, gadodiamide, Gadodiamide may decrease the excretion rate of Almotriptan which could result in a higher serum level.]
[C01CA15, gepefrine, The risk or severity of serotonin syndrome can be increased when Almotriptan is combined with Gepefrine.]
[N05CM08, ethchlorvynol, The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Almotriptan.]
[L02AA03, ethinyl estradiol, The metabolism of Almotriptan can be decreased when combined with Ethinylestradiol.]
[C01BD05, ibutilide, Ibutilide may decrease the excretion rate of Almotriptan which could result in a higher serum level.]
[N04AA05, profenamine, Almotriptan may increase the central nervous system depressant (CNS depressant) activities of Profenamine.]
[N03AD01, ethosuximide, The risk or severity of adverse effects can be increased when Ethosuximide is combined with Almotriptan.]
[N03AB01, ethotoin, The risk or severity of adverse effects can be increased when Ethotoin is combined with Almotriptan.]
[M01AC06, meloxicam, The risk or severity of hypertension can be increased when Meloxicam is combined with Almotriptan.]
[S01XA06, ethylmorphine, The risk or severity of adverse effects can be increased when Almotriptan is combined with Ethylmorphine.]
[C01CA01, etilefrine, The risk or severity of hypertension can be increased when Almotriptan is combined with Etilefrine.]
[N01AX07, etomidate, The risk or severity of adverse effects can be increased when Etomidate is combined with Almotriptan.]
[N05AE03, sertindole, The risk or severity of adverse effects can be increased when Almotriptan is combined with Sertindole.]
[L04AD02, tacrolimus, Tacrolimus may decrease the excretion rate of Almotriptan which could result in a higher serum level.]
[R06AX11, astemizole, The metabolism of Astemizole can be decreased when combined with Almotriptan.]
[R06AX12, terfenadine, The metabolism of Almotriptan can be decreased when combined with Terfenadine.]
[P01AX07, trimetrexate, Almotriptan may decrease the excretion rate of Trimetrexate which could result in a higher serum level.]
[N06AX12, bupropion, The metabolism of Almotriptan can be decreased when combined with Bupropion.]
[N06AB08, fluvoxamine, The metabolism of Almotriptan can be decreased when combined with Fluvoxamine.]
[C01BC08, encainide, The metabolism of Encainide can be decreased when combined with Almotriptan.]
[L02AE02, leuprolide, Leuprolide may decrease the excretion rate of Almotriptan which could result in a higher serum level.]
[M01CB01, gold sodium thiomalate, Almotriptan may decrease the excretion rate of Sodium aurothiomalate which could result in a higher serum level.]
[B05AA05, dextran, Almotriptan may decrease the excretion rate of Dextran which could result in a higher serum level.]
[V03AF02, dexrazoxane, Dexrazoxane may decrease the excretion rate of Almotriptan which could result in a higher serum level.]
[A16AA01, levocarnitine, Levocarnitine may decrease the excretion rate of Almotriptan which could result in a higher serum level.]
[C08CA02, felodipine, The metabolism of Almotriptan can be decreased when combined with Felodipine.]
[N03AX26, fenfluramine, The risk or severity of serotonin syndrome can be increased when Almotriptan is combined with Fenfluramine.]
[M01AE04, fenoprofen, The risk or severity of hypertension can be increased when Fenoprofen is combined with Almotriptan.]
[R03CC04, fenoterol, The risk or severity of hypertension can be increased when Almotriptan is combined with Fenoterol.]
[N02AB03, fentanyl, The risk or severity of adverse effects can be increased when Fentanyl is combined with Almotriptan.]
[R03CC02, albuterol, The risk or severity of hypertension can be increased when Almotriptan is combined with Salbutamol.]
[L01BB06, clofarabine, Clofarabine may decrease the excretion rate of Almotriptan which could result in a higher serum level.]
[N07AX03, cevimeline, Cevimeline may decrease the excretion rate of Almotriptan which could result in a higher serum level.]
[G04BD02, flavoxate, Almotriptan may increase the central nervous system depressant (CNS depressant) activities of Flavoxate.]
[C01BC04, flecainide, The metabolism of Flecainide can be decreased when combined with Almotriptan.]
[N02BG04, floctafenine, The risk or severity of hypertension can be increased when Almotriptan is combined with Floctafenine.]
[J02AC01, fluconazole, The metabolism of Almotriptan can be decreased when combined with Fluconazole.]
[J02AX01, flucytosine, Almotriptan may decrease the excretion rate of Flucytosine which could result in a higher serum level.]
[V03AB25, flumazenil, Almotriptan may decrease the excretion rate of Flumazenil which could result in a higher serum level.]
[N07CA03, flunarizine, The risk or severity of adverse effects can be increased when Almotriptan is combined with Flunarizine.]
[N05CD03, flunitrazepam, The risk or severity of adverse effects can be increased when Almotriptan is combined with Flunitrazepam.]
[N06AA14, melitracen, The risk or severity of adverse effects can be increased when Almotriptan is combined with Melitracen.]
[V03AZ01, ethanol, Almotriptan may increase the central nervous system depressant (CNS depressant) activities of Ethanol.]
[L01BC09, floxuridine, Floxuridine may decrease the excretion rate of Almotriptan which could result in a higher serum level.]
[L01BC02, fluorouracil, The metabolism of Fluorouracil can be decreased when combined with Almotriptan.]
[N06AB03, fluoxetine, The serum concentration of Almotriptan can be increased when it is combined with Fluoxetine.]
[N05AF01, flupenthixol, Almotriptan may increase the central nervous system depressant (CNS depressant) activities of Flupentixol.]
[N05AB02, fluphenazine, The risk or severity of adverse effects can be increased when Almotriptan is combined with Fluphenazine.]
[N05CD01, flurazepam, The risk or severity of adverse effects can be increased when Flurazepam is combined with Almotriptan.]
[S01BC04, flurbiprofen, The risk or severity of hypertension can be increased when Flurbiprofen is combined with Almotriptan.]
[N05AG01, fluspirilene, The risk or severity of adverse effects can be increased when Almotriptan is combined with Fluspirilene.]
[L02BB01, flutamide, Flutamide may decrease the excretion rate of Almotriptan which could result in a higher serum level.]
[V04CX02, folic acid, Folic acid may decrease the excretion rate of Almotriptan which could result in a higher serum level.]
[S02AA17, fosfomycin, Fosfomycin may decrease the excretion rate of Almotriptan which could result in a higher serum level.]
[S01AA07, framycetin, Framycetin may decrease the excretion rate of Almotriptan which could result in a higher serum level.]
[L01BC03, tegafur, The metabolism of Tegafur can be decreased when combined with Almotriptan.]
[N06BX17, adrafinil, The risk or severity of hypertension can be increased when Almotriptan is combined with Adrafinil.]
[M03AA01, alcuronium, The risk or severity of adverse effects can be increased when Almotriptan is combined with Alcuronium.]
[G01AX06, furazolidone, The metabolism of Almotriptan can be decreased when combined with Furazolidone.]
[J05AE10, darunavir, The metabolism of Almotriptan can be decreased when combined with Darunavir.]
[C03CA01, furosemide, Furosemide may increase the excretion rate of Almotriptan which could result in a lower serum level and potentially a reduction in efficacy.]
[N05CF04, eszopiclone, The risk or severity of CNS depression can be increased when Almotriptan is combined with Eszopiclone.]
[N05AL05, amisulpride, The risk or severity of adverse effects can be increased when Almotriptan is combined with Amisulpride.]
[N06DA04, galantamine, The metabolism of Almotriptan can be decreased when combined with Galantamine.]
[M03AC02, gallamine, The risk or severity of adverse effects can be increased when Almotriptan is combined with Gallamine.]
[S01AD09, ganciclovir, Almotriptan may decrease the excretion rate of Ganciclovir which could result in a higher serum level.]
[N03AA04, barbexaclone, The risk or severity of adverse effects can be increased when Almotriptan is combined with Barbexaclone.]
[N06AX08, bifemelane, The risk or severity of adverse effects can be increased when Almotriptan is combined with Bifemelane.]
[C10AB04, gemfibrozil, The metabolism of Almotriptan can be decreased when combined with Gemfibrozil.]
[J01XA03, telavancin, Almotriptan may decrease the excretion rate of Telavancin which could result in a higher serum level.]
[N04BC06, cabergoline, Cabergoline may increase the vasoconstricting activities of Almotriptan.]
[N03AD03, methsuximide, The risk or severity of adverse effects can be increased when Almotriptan is combined with Methsuximide.]
[N01AH02, alfentanil, The risk or severity of adverse effects can be increased when Alfentanil is combined with Almotriptan.]
[L01EH01, lapatinib, The metabolism of Lapatinib can be decreased when combined with Almotriptan.]
[A10BB07, glipizide, Almotriptan may decrease the excretion rate of Glipizide which could result in a higher serum level.]
[N05CM18, dexmedetomidine, The risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Almotriptan.]
[N05CE01, glutethimide, The risk or severity of adverse effects can be increased when Almotriptan is combined with Glutethimide.]
[C05AE01, nitroglycerin, Almotriptan may decrease the antihypertensive activities of Nitroglycerin.]
[C02CA04, doxazosin, Almotriptan may decrease the antihypertensive activities of Doxazosin.]
[L01EX02, sorafenib, The metabolism of Sorafenib can be decreased when combined with Almotriptan.]
[C07AB09, esmolol, Almotriptan may decrease the antihypertensive activities of Esmolol.]
[M01CB04, aurothioglucose, Almotriptan may decrease the excretion rate of Aurothioglucose which could result in a higher serum level.]
[S01LA03, pegaptanib, Almotriptan may decrease the excretion rate of Pegaptanib which could result in a higher serum level.]
[B01AA12, fluindione, The risk or severity of adverse effects can be increased when Almotriptan is combined with Fluindione.]
[C09AA09, fosinopril, Almotriptan may decrease the antihypertensive activities of Fosinopril.]
[S01EX01, guanethidine, Almotriptan may decrease the antihypertensive activities of Guanethidine.]
[L02AE03, goserelin, Goserelin may decrease the excretion rate of Almotriptan which could result in a higher serum level.]
[P01BX01, halofantrine, The metabolism of Almotriptan can be decreased when combined with Halofantrine.]
[N05AD01, haloperidol, The risk or severity of CNS depression can be increased when Haloperidol is combined with Almotriptan.]
[N01AB01, halothane, The risk or severity of adverse effects can be increased when Almotriptan is combined with Halothane.]
[N05AH04, quetiapine, Almotriptan may increase the central nervous system depressant (CNS depressant) activities of Quetiapine.]
[N06BX13, idebenone, Almotriptan may decrease the excretion rate of Idebenone which could result in a higher serum level.]
[N02CX03, iprazochrome, The risk or severity of adverse effects can be increased when Almotriptan is combined with Iprazochrome.]
[N05CA21, allobarbital, The risk or severity of adverse effects can be increased when Almotriptan is combined with Allobarbital.]
[M04AA01, allopurinol, Allopurinol may decrease the excretion rate of Almotriptan which could result in a higher serum level.]
[C09CA01, losartan, The metabolism of Almotriptan can be decreased when combined with Losartan.]
[G03DC01, allylestrenol, Almotriptan may decrease the excretion rate of Allylestrenol which could result in a higher serum level.]
[A07EC02, mesalamine, The risk or severity of hypertension can be increased when Mesalazine is combined with Almotriptan.]
[C01CE02, milrinone, Milrinone may decrease the excretion rate of Almotriptan which could result in a higher serum level.]
[N05CA16, hexobarbital, The risk or severity of adverse effects can be increased when Almotriptan is combined with Hexobarbital.]
[R03CC05, hexoprenaline, The risk or severity of hypertension can be increased when Almotriptan is combined with Hexoprenaline.]
[J05AG01, nevirapine, The metabolism of Almotriptan can be decreased when combined with Nevirapine.]
[C08CA10, nilvadipine, The metabolism of Almotriptan can be decreased when combined with Nilvadipine.]
[M02AA26, nimesulide, The risk or severity of hypertension can be increased when Almotriptan is combined with Nimesulide.]
[C09AA04, perindopril, Almotriptan may decrease the antihypertensive activities of Perindopril.]
[C02DB02, hydralazine, Almotriptan may decrease the antihypertensive activities of Hydralazine.]
[C03AA03, hydrochlorothiazide, Hydrochlorothiazide may increase the excretion rate of Almotriptan which could result in a lower serum level and potentially a reduction in efficacy.]
[R05DA03, hydrocodone, Almotriptan may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.]
[S02BA01, hydrocortisone, The metabolism of Almotriptan can be increased when combined with Hydrocortisone.]
[C03AA02, hydroflumethiazide, Hydroflumethiazide may increase the excretion rate of Almotriptan which could result in a lower serum level and potentially a reduction in efficacy.]
[B05XA17, potassium acetate, Almotriptan may decrease the excretion rate of Potassium acetate which could result in a higher serum level.]
[A12BA02, potassium citrate, Potassium citrate may increase the excretion rate of Almotriptan which could result in a lower serum level and potentially a reduction in efficacy.]
[V03AB33, hydroxocobalamin, Hydroxocobalamin may decrease the excretion rate of Almotriptan which could result in a higher serum level.]
[G04BD06, propiverine, Almotriptan may increase the central nervous system depressant (CNS depressant) activities of Propiverine.]
[P01BA02, hydroxychloroquine, The metabolism of Hydroxychloroquine can be decreased when combined with Almotriptan.]
[N05AX07, prothipendyl, The risk or severity of adverse effects can be increased when Almotriptan is combined with Prothipendyl.]
[B05AA07, hetastarch, Almotriptan may decrease the excretion rate of Hydroxyethyl Starch which could result in a higher serum level.]
[N05BB01, hydroxyzine, Hydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Almotriptan.]
[J04AB04, rifabutin, The metabolism of Almotriptan can be increased when combined with Rifabutin.]
[C02AC06, rilmenidine, Almotriptan may decrease the antihypertensive activities of Rilmenidine.]
[R02AX02, ibuprofen, The metabolism of Ibuprofen can be decreased when combined with Almotriptan.]
[B05XA08, sodium acetate, Almotriptan may decrease the excretion rate of Sodium acetate which could result in a higher serum level.]
[L01DB06, idarubicin, The metabolism of Idarubicin can be decreased when combined with Almotriptan.]
[L01AA06, ifosfamide, The metabolism of Almotriptan can be increased when combined with Ifosfamide.]
[N01AH03, sufentanil, The risk or severity of adverse effects can be increased when Sufentanil is combined with Almotriptan.]
[N06AA02, imipramine, The metabolism of Almotriptan can be decreased when combined with Imipramine.]
[L01CD01, paclitaxel, The metabolism of Paclitaxel can be decreased when combined with Almotriptan.]
[R01AD07, tixocortol, Almotriptan may decrease the excretion rate of Tixocortol which could result in a higher serum level.]
[M03BX02, tizanidine, The risk or severity of adverse effects can be increased when Tizanidine is combined with Almotriptan.]
[L01CE01, topotecan, Almotriptan may decrease the excretion rate of Topotecan which could result in a higher serum level.]
[C03BA11, indapamide, Indapamide may increase the excretion rate of Almotriptan which could result in a lower serum level and potentially a reduction in efficacy.]
[S01BC01, indomethacin, The risk or severity of hypertension can be increased when Indomethacin is combined with Almotriptan.]
[C02CA02, indoramin, Almotriptan may decrease the antihypertensive activities of Indoramin.]
[A11HA07, inositol, Almotriptan may decrease the excretion rate of Inositol which could result in a higher serum level.]
[N06AX17, milnacipran, The risk or severity of adverse effects can be increased when Almotriptan is combined with Milnacipran.]
[A03AA30, piperidolate, Almotriptan may increase the central nervous system depressant (CNS depressant) activities of Piperidolate.]
[S01XA28, varenicline, Almotriptan may decrease the excretion rate of Varenicline which could result in a higher serum level.]
[N01BB08, articaine, The risk or severity of adverse effects can be increased when Almotriptan is combined with Articaine.]
[A10BH01, sitagliptin, The metabolism of Sitagliptin can be decreased when combined with Almotriptan.]
[N05BA12, alprazolam, The risk or severity of adverse effects can be increased when Alprazolam is combined with Almotriptan.]
[N05CH02, ramelteon, The risk or severity of adverse effects can be increased when Almotriptan is combined with Ramelteon.]
[R06AE01, buclizine, Almotriptan may increase the central nervous system depressant (CNS depressant) activities of Buclizine.]
[C10AA06, cerivastatin, The metabolism of Almotriptan can be decreased when combined with Cerivastatin.]
[C07AA01, alprenolol, The risk or severity of adverse effects can be increased when Alprenolol is combined with Almotriptan.]
[C03BA02, quinethazone, Quinethazone may increase the excretion rate of Almotriptan which could result in a lower serum level and potentially a reduction in efficacy.]
[V03AB01, ipecac, Almotriptan may decrease the excretion rate of Ipecac which could result in a higher serum level.]
[N06AA13, iprindole, The risk or severity of adverse effects can be increased when Almotriptan is combined with Iprindole.]
[N06AF05, iproniazid, The metabolism of Almotriptan can be decreased when combined with Iproniazid.]
[N05AA07, chlorproethazine, The risk or severity of adverse effects can be increased when Almotriptan is combined with Chlorproethazine.]
[N06AF01, isocarboxazid, The metabolism of Almotriptan can be decreased when combined with Isocarboxazid.]
[R03CC06, isoetharine, The risk or severity of hypertension can be increased when Isoetharine is combined with Almotriptan.]
[C09AA16, imidapril, Almotriptan may decrease the antihypertensive activities of Imidapril.]
[N01AB06, isoflurane, The risk or severity of adverse effects can be increased when Isoflurane is combined with Almotriptan.]
[N04BX02, entacapone, The risk or severity of adverse effects can be increased when Entacapone is combined with Almotriptan.]
[J04AC01, isoniazid, The metabolism of Almotriptan can be decreased when combined with Isoniazid.]
[J05AX05, inosine pranobex, Almotriptan may decrease the excretion rate of Inosine pranobex which could result in a higher serum level.]
[R03CB01, isoproterenol, The risk or severity of hypertension can be increased when Almotriptan is combined with Isoprenaline.]
[C01DA14, isosorbide mononitrate, Almotriptan may decrease the excretion rate of Isosorbide mononitrate which could result in a higher serum level.]
[D10BA01, isotretinoin, Almotriptan may decrease the excretion rate of Isotretinoin which could result in a higher serum level.]
[C04AA01, isoxsuprine, The risk or severity of hypertension can be increased when Almotriptan is combined with Isoxsuprine.]
[N06AX18, reboxetine, The risk or severity of adverse effects can be increased when Reboxetine is combined with Almotriptan.]
[S01AA24, kanamycin, Almotriptan may decrease the excretion rate of Kanamycin which could result in a higher serum level.]
[L04AC07, tocilizumab, The metabolism of Almotriptan can be increased when combined with Tocilizumab.]
[N01AX03, ketamine, The risk or severity of adverse effects can be increased when Almotriptan is combined with Ketamine.]
[C02KD01, ketanserin, The risk or severity of adverse effects can be increased when Almotriptan is combined with Ketanserin.]
[B01AC22, prasugrel, Almotriptan may decrease the excretion rate of Prasugrel which could result in a higher serum level.]
[J02AB02, ketoconazole, The metabolism of Almotriptan can be decreased when combined with Ketoconazole.]
[N05AH03, olanzapine, Almotriptan may increase the central nervous system depressant (CNS depressant) activities of Olanzapine.]
[M02AA10, ketoprofen, The risk or severity of hypertension can be increased when Almotriptan is combined with Ketoprofen.]
[V03AC03, deferasirox, The metabolism of Almotriptan can be decreased when combined with Deferasirox.]
[L04AA24, abatacept, The metabolism of Almotriptan can be increased when combined with Abatacept.]
[C01CA22, arbutamine, The risk or severity of hypertension can be increased when Almotriptan is combined with Arbutamine.]
[N04BC09, rotigotine, Almotriptan may increase the sedative activities of Rotigotine.]
[M01AE11, tiaprofenic acid, The risk or severity of hypertension can be increased when Almotriptan is combined with Tiaprofenic acid.]
[C07AG01, labetalol, The metabolism of Almotriptan can be decreased when combined with Labetalol.]
[N04BB01, amantadine, The risk or severity of serotonin syndrome can be increased when Amantadine is combined with Almotriptan.]
[C02AA05, deserpidine, Almotriptan may decrease the antihypertensive activities of Deserpidine.]
[A06AX03, lubiprostone, Almotriptan may decrease the excretion rate of Lubiprostone which could result in a higher serum level.]
[N03AX18, lacosamide, The risk or severity of adverse effects can be increased when Almotriptan is combined with Lacosamide.]
[C03CC01, ethacrynic acid, Etacrynic acid may increase the excretion rate of Almotriptan which could result in a lower serum level and potentially a reduction in efficacy.]
[N04BA01, levodopa, The risk or severity of adverse effects can be increased when Almotriptan is combined with Levodopa.]
[S02DA01, lidocaine, The risk or severity of adverse effects can be increased when Lidocaine is combined with Almotriptan.]
[S01AA21, amikacin, Almotriptan may decrease the excretion rate of Amikacin which could result in a higher serum level.]
[C03DB01, amiloride, Amiloride may increase the excretion rate of Almotriptan which could result in a lower serum level and potentially a reduction in efficacy.]
[N02CA07, lisuride, Lisuride may increase the vasoconstricting activities of Almotriptan.]
[N06AA07, lofepramine, The risk or severity of adverse effects can be increased when Almotriptan is combined with Lofepramine.]
[A07DA03, loperamide, The metabolism of Almotriptan can be decreased when combined with Loperamide.]
[N05BA06, lorazepam, The risk or severity of adverse effects can be increased when Lorazepam is combined with Almotriptan.]
[C10AA02, lovastatin, The metabolism of Almotriptan can be decreased when combined with Lovastatin.]
[N05AH01, loxapine, The risk or severity of adverse effects can be increased when Almotriptan is combined with Loxapine.]
[L01EG01, temsirolimus, The metabolism of Almotriptan can be decreased when combined with Temsirolimus.]
[B05XA11, magnesium chloride, Almotriptan may decrease the excretion rate of Magnesium chloride which could result in a higher serum level.]
[G04BX01, magnesium hydroxide, Almotriptan may decrease the excretion rate of Magnesium hydroxide which could result in a higher serum level.]
[V04CC02, magnesium sulfate, The therapeutic efficacy of Almotriptan can be increased when used in combination with Magnesium sulfate.]
[L01BA05, pralatrexate, Almotriptan may decrease the excretion rate of Pralatrexate which could result in a higher serum level.]
[L01EA03, nilotinib, The metabolism of Almotriptan can be decreased when combined with Nilotinib.]
[V04CX04, mannitol, Mannitol may increase the excretion rate of Almotriptan which could result in a lower serum level and potentially a reduction in efficacy.]
[N06AA21, maprotiline, Almotriptan may increase the central nervous system depressant (CNS depressant) activities of Maprotiline.]
[A08AA05, mazindol, The risk or severity of adverse effects can be increased when Mazindol is combined with Almotriptan.]
[C02BB01, mecamylamine, Almotriptan may decrease the antihypertensive activities of Mecamylamine.]
[R06AE05, meclizine, The risk or severity of adverse effects can be increased when Meclizine is combined with Almotriptan.]
[M02AA18, meclofenamic acid, The risk or severity of hypertension can be increased when Almotriptan is combined with Meclofenamic acid.]
[N05BA03, medazepam, The risk or severity of adverse effects can be increased when Almotriptan is combined with Medazepam.]
[C03BA05, mefruside, Mefruside may increase the excretion rate of Almotriptan which could result in a lower serum level and potentially a reduction in efficacy.]
[N05CH01, melatonin, The risk or severity of adverse effects can be increased when Almotriptan is combined with Melatonin.]
[N06DX01, memantine, Almotriptan may decrease the excretion rate of Memantine which could result in a higher serum level.]
[N02AB02, meperidine, The risk or severity of adverse effects can be increased when Meperidine is combined with Almotriptan.]
[C01CA11, mephentermine, The risk or severity of serotonin syndrome can be increased when Almotriptan is combined with Mephentermine.]
[N03AB04, mephenytoin, The risk or severity of adverse effects can be increased when Mephenytoin is combined with Almotriptan.]
[N03AA01, mephobarbital, The risk or severity of adverse effects can be increased when Methylphenobarbital is combined with Almotriptan.]
[N01BB03, mepivacaine, The risk or severity of adverse effects can be increased when Almotriptan is combined with Mepivacaine.]
[N05BC01, meprobamate, The risk or severity of adverse effects can be increased when Meprobamate is combined with Almotriptan.]
[N02AX05, meptazinol, The risk or severity of adverse effects can be increased when Almotriptan is combined with Meptazinol.]
[G04BX16, tiopronin, Almotriptan may decrease the excretion rate of Tiopronin which could result in a higher serum level.]
[C03BC01, mersalyl, Mersalyl may increase the excretion rate of Almotriptan which could result in a lower serum level and potentially a reduction in efficacy.]
[N05AC03, mesoridazine, The risk or severity of adverse effects can be increased when Almotriptan is combined with Mesoridazine.]
[N05AX13, paliperidone, The risk or severity of adverse effects can be increased when Almotriptan is combined with Paliperidone.]
[C01CA09, metaraminol, The risk or severity of hypertension can be increased when Metaraminol is combined with Almotriptan.]
[A10BA02, metformin, Metformin may decrease the excretion rate of Almotriptan which could result in a higher serum level.]
[A04AA04, dolasetron, The risk or severity of adverse effects can be increased when Dolasetron is combined with Almotriptan.]
[N07BC02, methadone, The risk or severity of adverse effects can be increased when Methadone is combined with Almotriptan.]
[N06BA03, methamphetamine, The metabolism of Almotriptan can be decreased when combined with Metamfetamine.]
[A03AB07, methantheline, Almotriptan may increase the central nervous system depressant (CNS depressant) activities of Methantheline.]
[R06AC05, methapyrilene, The risk or severity of adverse effects can be increased when Almotriptan is combined with Methapyrilene.]
[N05CM01, methaqualone, The risk or severity of adverse effects can be increased when Almotriptan is combined with Methaqualone.]
[J05AF05, lamivudine, Lamivudine may decrease the excretion rate of Almotriptan which could result in a higher serum level.]
[N03AA30, metharbital, The risk or severity of adverse effects can be increased when Metharbital is combined with Almotriptan.]
[S01EC05, methazolamide, Methazolamide may increase the excretion rate of Almotriptan which could result in a lower serum level and potentially a reduction in efficacy.]
[G02CB05, metergoline, Metergoline may increase the vasoconstricting activities of Almotriptan.]
[H03BB02, methimazole, The metabolism of Almotriptan can be decreased when combined with Methimazole.]
[L01BA04, pemetrexed, Almotriptan may decrease the excretion rate of Pemetrexed which could result in a higher serum level.]
[M03BA03, methocarbamol, The risk or severity of adverse effects can be increased when Methocarbamol is combined with Almotriptan.]
[N05CA15, methohexital, The risk or severity of adverse effects can be increased when Methohexital is combined with Almotriptan.]
[A11HA02, pyridoxine, Pyridoxine may decrease the excretion rate of Almotriptan which could result in a higher serum level.]
[N02BG08, ziconotide, The risk or severity of adverse effects can be increased when Almotriptan is combined with Ziconotide.]
[L04AX03, methotrexate, Methotrexate may decrease the excretion rate of Almotriptan which could result in a higher serum level.]
[N05AA02, methotrimeprazine, Almotriptan may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.]
[C01CA10, methoxamine, The risk or severity of hypertension can be increased when Methoxamine is combined with Almotriptan.]
[D05BA02, methoxsalen, Methoxsalen may decrease the excretion rate of Almotriptan which could result in a higher serum level.]
[N02BG09, methoxyflurane, The risk or severity of adverse effects can be increased when Almotriptan is combined with Methoxyflurane.]
[C03AA08, methyclothiazide, Methyclothiazide may increase the excretion rate of Almotriptan which could result in a lower serum level and potentially a reduction in efficacy.]
[C02AB01, methyldopa, Almotriptan may decrease the antihypertensive activities of Methyldopa.]
[V04CG05, methylene blue, Almotriptan may increase the serotonergic activities of Methylene blue.]
[G02AB01, methylergonovine, Methylergometrine may increase the vasoconstricting activities of Almotriptan.]
[N06BA04, methylphenidate, The risk or severity of hypertension can be increased when Methylphenidate is combined with Almotriptan.]
[N03AF03, rufinamide, The risk or severity of adverse effects can be increased when Rufinamide is combined with Almotriptan.]
[G03EK01, methyltestosterone, Almotriptan may decrease the excretion rate of Methyltestosterone which could result in a higher serum level.]
[N05CE02, methyprylon, The risk or severity of adverse effects can be increased when Almotriptan is combined with Methyprylon.]
[N02CA04, methysergide, Methysergide may increase the vasoconstricting activities of Almotriptan.]
[A03FA01, metoclopramide, The risk or severity of sedation can be increased when Metoclopramide is combined with Almotriptan.]
[C03BA08, metolazone, Metolazone may increase the excretion rate of Almotriptan which could result in a lower serum level and potentially a reduction in efficacy.]
[C07AB02, metoprolol, The metabolism of Almotriptan can be decreased when combined with Metoprolol.]
[P01AB01, metronidazole, The metabolism of Almotriptan can be decreased when combined with Metronidazole.]
[V04CD01, metyrapone, Almotriptan may decrease the excretion rate of Metyrapone which could result in a higher serum level.]
[C01BB02, mexiletine, The metabolism of Almotriptan can be decreased when combined with Mexiletine.]
[N06AX03, mianserin, The risk or severity of adverse effects can be increased when Almotriptan is combined with Mianserin.]
[S02AA13, miconazole, The metabolism of Almotriptan can be decreased when combined with Miconazole.]
[N02BB03, aminopyrine, The metabolism of Aminophenazone can be decreased when combined with Almotriptan.]
[N05CD08, midazolam, The risk or severity of adverse effects can be increased when Midazolam is combined with Almotriptan.]
[C01CA17, midodrine, The risk or severity of hypertension can be increased when Midodrine is combined with Almotriptan.]
[G03XB01, mifepristone, The serum concentration of Almotriptan can be increased when it is combined with Mifepristone.]
[J05AH01, zanamivir, Zanamivir may decrease the excretion rate of Almotriptan which could result in a higher serum level.]
[C09CA03, valsartan, Almotriptan may decrease the antihypertensive activities of Valsartan.]
[J01AA08, minocycline, Minocycline may increase the central nervous system depressant (CNS depressant) activities of Almotriptan.]
[D11AX01, minoxidil, Almotriptan may decrease the antihypertensive activities of Minoxidil.]
[L01XX23, mitotane, The metabolism of Almotriptan can be increased when combined with Mitotane.]
[N06BA12, lisdexamfetamine, The risk or severity of serotonin syndrome can be increased when Almotriptan is combined with Lisdexamfetamine.]
[N05AE02, molindone, The risk or severity of adverse effects can be increased when Almotriptan is combined with Molindone.]
[L03AC01, aldesleukin, Aldesleukin may decrease the excretion rate of Almotriptan which could result in a higher serum level.]
[C01BD01, amiodarone, The metabolism of Almotriptan can be decreased when combined with Amiodarone.]
[N06AA09, amitriptyline, The metabolism of Amitriptyline can be decreased when combined with Almotriptan.]
[N02AA01, morphine, The risk or severity of adverse effects can be increased when Morphine is combined with Almotriptan.]
[A04AA05, palonosetron, The risk or severity of adverse effects can be increased when Palonosetron is combined with Almotriptan.]
[J01DD06, moxalactam, Latamoxef may decrease the excretion rate of Almotriptan which could result in a higher serum level.]
[L04AB05, certolizumab pegol, The metabolism of Almotriptan can be increased when combined with Certolizumab pegol.]
[B02BX05, eltrombopag, The metabolism of Almotriptan can be decreased when combined with Eltrombopag.]
[G04BA01, ammonium chloride, Almotriptan may decrease the excretion rate of Ammonium chloride which could result in a higher serum level.]
[L01EX03, pazopanib, The metabolism of Pazopanib can be decreased when combined with Almotriptan.]
[L04AA06, mycophenolic acid, Almotriptan may decrease the excretion rate of Mycophenolic acid which could result in a higher serum level.]
[M03AC03, vecuronium, The risk or severity of adverse effects can be increased when Almotriptan is combined with Vecuronium.]
[N05CA02, amobarbital, The risk or severity of adverse effects can be increased when Almotriptan is combined with Amobarbital.]
[P01BA06, amodiaquine, The metabolism of Almotriptan can be decreased when combined with Amodiaquine.]
[G03XC01, raloxifene, The metabolism of Almotriptan can be decreased when combined with Raloxifene.]
[N06AA17, amoxapine, The metabolism of Amoxapine can be decreased when combined with Almotriptan.]
[N03AB05, fosphenytoin, The metabolism of Fosphenytoin can be decreased when combined with Almotriptan.]
[C07AA12, nadolol, Almotriptan may decrease the antihypertensive activities of Nadolol.]
[J01CA04, amoxicillin, Almotriptan may decrease the excretion rate of Amoxicillin which could result in a higher serum level.]
[N04BC04, ropinirole, Almotriptan may increase the sedative activities of Ropinirole.]
[C04AX21, nafronyl, The risk or severity of adverse effects can be increased when Almotriptan is combined with Naftidrofuryl.]
[N02AF02, nalbuphine, The risk or severity of adverse effects can be increased when Nalbuphine is combined with Almotriptan.]
[V03AB15, naloxone, The metabolism of Almotriptan can be decreased when combined with Naloxone.]
[N07BB04, naltrexone, The risk or severity of serotonin syndrome can be increased when Naltrexone is combined with Almotriptan.]
[L04AC03, anakinra, The metabolism of Almotriptan can be increased when combined with Anakinra.]
[S01GA01, naphazoline, The risk or severity of hypertension can be increased when Almotriptan is combined with Naphazoline.]
[N06BA01, amphetamine, The risk or severity of serotonin syndrome can be increased when Amphetamine is combined with Almotriptan.]
[M02AA12, naproxen, The metabolism of Almotriptan can be decreased when combined with Naproxen.]
[A10BG01, troglitazone, The metabolism of Almotriptan can be decreased when combined with Troglitazone.]
[N06AX21, duloxetine, The metabolism of Almotriptan can be decreased when combined with Duloxetine.]
[N04BX01, tolcapone, The risk or severity of adverse effects can be increased when Tolcapone is combined with Almotriptan.]
[S03AA01, neomycin, Almotriptan may decrease the excretion rate of Neomycin which could result in a higher serum level.]
[N01AH06, remifentanil, The risk or severity of adverse effects can be increased when Remifentanil is combined with Almotriptan.]
[A10BX02, repaglinide, The metabolism of Almotriptan can be decreased when combined with Repaglinide.]
[B01AC17, tirofiban, Tirofiban may decrease the excretion rate of Almotriptan which could result in a higher serum level.]
[N05AX14, iloperidone, The risk or severity of adverse effects can be increased when Almotriptan is combined with Iloperidone.]
[J02AA01, amphotericin B, Amphotericin B may decrease the excretion rate of Almotriptan which could result in a higher serum level.]
[S01AA19, ampicillin, Ampicillin may decrease the excretion rate of Almotriptan which could result in a higher serum level.]
[L03AX16, plerixafor, Almotriptan may decrease the excretion rate of Plerixafor which could result in a higher serum level.]
[S01AA23, netilmicin, Almotriptan may decrease the excretion rate of Netilmicin which could result in a higher serum level.]
[N06AX23, desvenlafaxine, The risk or severity of adverse effects can be increased when Almotriptan is combined with Desvenlafaxine.]
[C09CA07, telmisartan, Almotriptan may decrease the antihypertensive activities of Telmisartan.]
[J05AB11, valacyclovir, Valaciclovir may decrease the excretion rate of Almotriptan which could result in a higher serum level.]
[C01CE01, inamrinone, Almotriptan may decrease the excretion rate of Amrinone which could result in a higher serum level.]
[C10AD02, niacin, The metabolism of Almotriptan can be decreased when combined with Niacin.]
[N06AF02, nialamide, The metabolism of Almotriptan can be decreased when combined with Nialamide.]
[C08CA04, nicardipine, The metabolism of Almotriptan can be decreased when combined with Nicardipine.]
[C04AE02, nicergoline, Nicergoline may increase the vasoconstricting activities of Almotriptan.]
[N07BA01, nicotine, The metabolism of Almotriptan can be decreased when combined with Nicotine.]
[C08CA05, nifedipine, Almotriptan may decrease the excretion rate of Nifedipine which could result in a higher serum level.]
[M02AA17, niflumic acid, The risk or severity of hypertension can be increased when Almotriptan is combined with Niflumic acid.]
[C08CA06, nimodipine, Almotriptan may decrease the antihypertensive activities of Nimodipine.]
[C08CA07, nisoldipine, Almotriptan may decrease the antihypertensive activities of Nisoldipine.]
[N05CD02, nitrazepam, The risk or severity of adverse effects can be increased when Almotriptan is combined with Nitrazepam.]
[C08CA08, nitrendipine, Almotriptan may decrease the antihypertensive activities of Nitrendipine.]
[R07AX01, nitric oxide, Nitric Oxide may decrease the excretion rate of Almotriptan which could result in a higher serum level.]
[J01XE01, nitrofurantoin, Nitrofurantoin may decrease the excretion rate of Almotriptan which could result in a higher serum level.]
[N05CF03, zaleplon, The risk or severity of adverse effects can be increased when Almotriptan is combined with Zaleplon.]
[N04BC05, pramipexole, Almotriptan may increase the sedative activities of Pramipexole.]
[C02DD01, nitroprusside, Almotriptan may decrease the antihypertensive activities of Nitroprusside.]
[N01AX13, nitrous oxide, The risk or severity of adverse effects can be increased when Almotriptan is combined with Nitrous oxide.]
[N06AX04, nomifensine, The risk or severity of adverse effects can be increased when Almotriptan is combined with Nomifensine.]
[C01CA03, norepinephrine, The risk or severity of hypertension can be increased when Norepinephrine is combined with Almotriptan.]
[C02KX01, bosentan, Almotriptan may decrease the antihypertensive activities of Bosentan.]
[N06AA10, nortriptyline, The metabolism of Nortriptyline can be decreased when combined with Almotriptan.]
[G02CA02, nylidrin, The risk or severity of hypertension can be increased when Almotriptan is combined with Nylidrin.]
[L04AC04, rilonacept, The metabolism of Almotriptan can be increased when combined with Rilonacept.]
[A02BC01, omeprazole, The metabolism of Almotriptan can be decreased when combined with Omeprazole.]
[N06AA05, opipramol, The risk or severity of adverse effects can be increased when Almotriptan is combined with Opipramol.]
[N02AA02, opium, The risk or severity of adverse effects can be increased when Almotriptan is combined with Opium.]
[R03CB03, metaproterenol, The risk or severity of hypertension can be increased when Orciprenaline is combined with Almotriptan.]
[G04CA02, tamsulosin, Tamsulosin may decrease the excretion rate of Almotriptan which could result in a higher serum level.]
[J01CF04, oxacillin, Oxacillin may decrease the excretion rate of Almotriptan which could result in a higher serum level.]
[P02BA02, oxamniquine, The metabolism of Almotriptan can be decreased when combined with Oxamniquine.]
[N05BA04, oxazepam, The risk or severity of adverse effects can be increased when Oxazepam is combined with Almotriptan.]
[C07AA02, oxprenolol, The risk or severity of adverse effects can be increased when Almotriptan is combined with Oxprenolol.]
[N02AA05, oxycodone, The risk or severity of adverse effects can be increased when Oxycodone is combined with Almotriptan.]
[C01DX03, oxyfedrine, The risk or severity of hypertension can be increased when Almotriptan is combined with Oxyfedrine.]
[S01GA04, oxymetazoline, The risk or severity of hypertension can be increased when Almotriptan is combined with Oxymetazoline.]
[N02AA11, oxymorphone, The risk or severity of adverse effects can be increased when Almotriptan is combined with Oxymorphone.]
[N05AE01, oxypertine, The risk or severity of adverse effects can be increased when Almotriptan is combined with Oxypertine.]
[S01BC02, oxyphenbutazone, The risk or severity of hypertension can be increased when Almotriptan is combined with Oxyphenbutazone.]
[A03AB03, oxyphenonium, Almotriptan may increase the central nervous system depressant (CNS depressant) activities of Oxyphenonium.]
[N05AH05, asenapine, The risk or severity of adverse effects can be increased when Almotriptan is combined with Asenapine.]
[N02AX06, tapentadol, Tapentadol may increase the central nervous system depressant (CNS depressant) activities of Almotriptan.]
[M03AC01, pancuronium, Almotriptan may increase the central nervous system depressant (CNS depressant) activities of Pancuronium.]
[J04AB30, capreomycin, Almotriptan may decrease the excretion rate of Capreomycin which could result in a higher serum level.]
[N05CC05, paraldehyde, Almotriptan may increase the central nervous system depressant (CNS depressant) activities of Paraldehyde.]
[C02KC01, pargyline, The metabolism of Almotriptan can be decreased when combined with Pargyline.]
[A07AA06, paromomycin, Paromomycin may decrease the excretion rate of Almotriptan which could result in a higher serum level.]
[G04BD11, fesoterodine, Almotriptan may increase the central nervous system depressant (CNS depressant) activities of Fesoterodine.]
[C07AA23, penbutolol, The risk or severity of adverse effects can be increased when Almotriptan is combined with Penbutolol.]
[N05AG03, penfluridol, The risk or severity of adverse effects can be increased when Almotriptan is combined with Penfluridol.]
[J01CE09, penicillin G procaine, Almotriptan may decrease the excretion rate of Procaine benzylpenicillin which could result in a higher serum level.]
[N02AD01, pentazocine, The risk or severity of adverse effects can be increased when Pentazocine is combined with Almotriptan.]
[N05CA01, pentobarbital, The metabolism of Almotriptan can be increased when combined with Pentobarbital.]
[L01XX08, pentostatin, Almotriptan may decrease the excretion rate of Pentostatin which could result in a higher serum level.]
[C04AD03, pentoxifylline, Pentoxifylline may decrease the excretion rate of Almotriptan which could result in a higher serum level.]
[N05AB10, perazine, The risk or severity of adverse effects can be increased when Almotriptan is combined with Perazine.]
[N04BC02, pergolide, Pergolide may increase the vasoconstricting activities of Almotriptan.]
[C08EX02, perhexiline, The metabolism of Almotriptan can be decreased when combined with Perhexiline.]
[N05AB03, perphenazine, The risk or severity of adverse effects can be increased when Almotriptan is combined with Perphenazine.]
[N02BE03, phenacetin, The metabolism of Phenacetin can be decreased when combined with Almotriptan.]
[N02AD02, phenazocine, The risk or severity of adverse effects can be increased when Almotriptan is combined with Phenazocine.]
[G04BX06, phenazopyridine, Phenazopyridine may decrease the excretion rate of Almotriptan which could result in a higher serum level.]
[N06AF03, phenelzine, The metabolism of Almotriptan can be decreased when combined with Phenelzine.]
[A10BA01, phenformin, The metabolism of Almotriptan can be decreased when combined with Phenformin.]
[B01AA02, phenindione, The risk or severity of adverse effects can be increased when Almotriptan is combined with Phenindione.]
[N03AA02, phenobarbital, The metabolism of Almotriptan can be increased when combined with Phenobarbital.]
[N01AH04, phenoperidine, The risk or severity of adverse effects can be increased when Almotriptan is combined with Phenoperidine.]
[C04AX02, phenoxybenzamine, Almotriptan may decrease the antihypertensive activities of Phenoxybenzamine.]
[B01AA04, phenprocoumon, The metabolism of Phenprocoumon can be decreased when combined with Almotriptan.]
[A08AA01, phentermine, The metabolism of Almotriptan can be decreased when combined with Phentermine.]
[V03AB36, phentolamine, Almotriptan may decrease the antihypertensive activities of Phentolamine.]
[M02AA01, phenylbutazone, The risk or severity of hypertension can be increased when Phenylbutazone is combined with Almotriptan.]
[S01GA05, phenylephrine, The risk or severity of hypertension can be increased when Phenylephrine is combined with Almotriptan.]
[R01BA01, phenylpropanolamine, The metabolism of Almotriptan can be decreased when combined with Phenylpropanolamine.]
[N03AB02, phenytoin, The metabolism of Phenytoin can be decreased when combined with Almotriptan.]
[L04AB06, golimumab, The metabolism of Almotriptan can be increased when combined with Golimumab.]
[S01AE05, levofloxacin, Almotriptan may decrease the excretion rate of Levofloxacin which could result in a higher serum level.]
[B02BA01, vitamin K1, Almotriptan may decrease the excretion rate of Phylloquinone which could result in a higher serum level.]
[J05AB12, cidofovir, Cidofovir may decrease the excretion rate of Almotriptan which could result in a higher serum level.]
[C08CX01, mibefradil, The metabolism of Almotriptan can be decreased when combined with Mibefradil.]
[N05AG02, pimozide, The metabolism of Pimozide can be decreased when combined with Almotriptan.]
[C07AA03, pindolol, The risk or severity of adverse effects can be increased when Almotriptan is combined with Pindolol.]
[C10AA05, atorvastatin, The metabolism of Atorvastatin can be decreased when combined with Almotriptan.]
[J01CA12, piperacillin, Piperacillin may decrease the excretion rate of Almotriptan which could result in a higher serum level.]
[J05AE01, saquinavir, The metabolism of Almotriptan can be decreased when combined with Saquinavir.]
[P02CB01, piperazine, The metabolism of Almotriptan can be decreased when combined with Piperazine.]
[N05AC04, pipothiazine, The risk or severity of adverse effects can be increased when Almotriptan is combined with Pipotiazine.]
[N06BX03, piracetam, Almotriptan may decrease the excretion rate of Piracetam which could result in a higher serum level.]
[C09CA02, eprosartan, Almotriptan may decrease the antihypertensive activities of Eprosartan.]
[A02BX03, pirenzepine, Almotriptan may increase the central nervous system depressant (CNS depressant) activities of Pirenzepine.]
[N02AC03, pirinitramide, The risk or severity of adverse effects can be increased when Almotriptan is combined with Piritramide.]
[S01BC06, piroxicam, The metabolism of Almotriptan can be decreased when combined with Piroxicam.]
[J01DD16, cefditoren, Cefditoren may decrease the excretion rate of Almotriptan which could result in a higher serum level.]
[N02CX01, pizotyline, Almotriptan may increase the central nervous system depressant (CNS depressant) activities of Pizotifen.]
[J05AG02, delavirdine, The metabolism of Almotriptan can be decreased when combined with Delavirdine.]
[C09CA04, irbesartan, The metabolism of Almotriptan can be decreased when combined with Irbesartan.]
[N05CA22, proxibarbal, The risk or severity of adverse effects can be increased when Almotriptan is combined with Proxibarbal.]
[D05AX05, tazarotene, The metabolism of Almotriptan can be decreased when combined with Tazarotene.]
[A10BG02, rosiglitazone, The metabolism of Almotriptan can be decreased when combined with Rosiglitazone.]
[L02BG03, anastrozole, The metabolism of Anastrozole can be decreased when combined with Almotriptan.]
[A03AE01, alosetron, The risk or severity of adverse effects can be increased when Almotriptan is combined with Alosetron.]
[L04AC08, canakinumab, The metabolism of Almotriptan can be increased when combined with Canakinumab.]
[C03AA05, polythiazide, Polythiazide may increase the excretion rate of Almotriptan which could result in a lower serum level and potentially a reduction in efficacy.]
[J05AE03, ritonavir, The metabolism of Almotriptan can be decreased when combined with Ritonavir.]
[A10BH03, saxagliptin, Almotriptan may decrease the excretion rate of Saxagliptin which could result in a higher serum level.]
[B05XA01, potassium chloride, Potassium chloride may decrease the excretion rate of Almotriptan which could result in a higher serum level.]
[C10AA08, pitavastatin, The metabolism of Pitavastatin can be decreased when combined with Almotriptan.]
[C07AB01, practolol, Almotriptan may decrease the antihypertensive activities of Practolol.]
[N05BA11, prazepam, The risk or severity of adverse effects can be increased when Almotriptan is combined with Prazepam.]
[C02CA01, prazosin, Almotriptan may decrease the antihypertensive activities of Prazosin.]
[H02AB07, prednisone, Prednisone may decrease the excretion rate of Almotriptan which could result in a higher serum level.]
[N01BB04, prilocaine, The risk or severity of adverse effects can be increased when Prilocaine is combined with Almotriptan.]
[P01BA03, primaquine, The metabolism of Almotriptan can be decreased when combined with Primaquine.]
[N03AA03, primidone, The metabolism of Almotriptan can be increased when combined with Primidone.]
[M04AB01, probenecid, The metabolism of Almotriptan can be increased when combined with Probenecid.]
[C01BA02, procainamide, The metabolism of Procainamide can be decreased when combined with Almotriptan.]
[S01HA05, procaine, The metabolism of Almotriptan can be decreased when combined with Procaine.]
[L01XB01, procarbazine, The metabolism of Almotriptan can be decreased when combined with Procarbazine.]
[C10AB05, fenofibrate, Almotriptan may decrease the excretion rate of Fenofibrate which could result in a higher serum level.]
[N05AB04, prochlorperazine, The risk or severity of adverse effects can be increased when Almotriptan is combined with Prochlorperazine.]
[N04AA04, procyclidine, Almotriptan may increase the central nervous system depressant (CNS depressant) activities of Procyclidine.]
[G03DA04, progesterone, The metabolism of Almotriptan can be decreased when combined with Progesterone.]
[N05AA03, promazine, Almotriptan may increase the central nervous system depressant (CNS depressant) activities of Promazine.]
[R06AD02, promethazine, Almotriptan may increase the central nervous system depressant (CNS depressant) activities of Promethazine.]
[C01BC03, propafenone, The metabolism of Almotriptan can be decreased when combined with Propafenone.]
[N01AX04, propanidid, The risk or severity of adverse effects can be increased when Almotriptan is combined with Propanidid.]
[A03AB05, propantheline, Almotriptan may increase the central nervous system depressant (CNS depressant) activities of Propantheline.]
[N05AC01, periciazine, The risk or severity of adverse effects can be increased when Almotriptan is combined with Periciazine.]
[N05CM06, propiomazine, Almotriptan may increase the central nervous system depressant (CNS depressant) activities of Propiomazine.]
[N01AX10, propofol, The risk or severity of adverse effects can be increased when Propofol is combined with Almotriptan.]
[N02AC04, propoxyphene, The risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Almotriptan.]
[C07AA05, propranolol, The metabolism of Almotriptan can be decreased when combined with Propranolol.]
[N02CC04, rizatriptan, The risk or severity of adverse effects can be increased when Almotriptan is combined with Rizatriptan.]
[B01AC09, epoprostenol, Almotriptan may decrease the antihypertensive activities of Epoprostenol.]
[R03DC03, montelukast, The metabolism of Almotriptan can be decreased when combined with Montelukast.]
[N06AA11, protriptyline, The risk or severity of adverse effects can be increased when Protriptyline is combined with Almotriptan.]
[R01BA02, pseudoephedrine, The metabolism of Almotriptan can be decreased when combined with Pseudoephedrine.]
[N05AX12, aripiprazole, Almotriptan may increase the central nervous system depressant (CNS depressant) activities of Aripiprazole.]
[N07XX07, dalfampridine, Almotriptan may decrease the excretion rate of Dalfampridine which could result in a higher serum level.]
[A03AB15, diphemanil, Almotriptan may increase the central nervous system depressant (CNS depressant) activities of Diphemanil.]
[A03AB09, isopropamide, Almotriptan may increase the central nervous system depressant (CNS depressant) activities of Isopropamide.]
[S01FA03, methscopolamine, Almotriptan may increase the central nervous system depressant (CNS depressant) activities of Methscopolamine.]
[N05CA07, talbutal, The risk or severity of adverse effects can be increased when Talbutal is combined with Almotriptan.]
[N05CA09, vinbarbital, The risk or severity of adverse effects can be increased when Almotriptan is combined with Vinbarbital.]
[N05BB02, captodiamine, The risk or severity of adverse effects can be increased when Almotriptan is combined with Captodiame.]
[M03BA04, styramate, The risk or severity of adverse effects can be increased when Almotriptan is combined with Styramate.]
[P02CC01, pyrantel, The risk or severity of adverse effects can be increased when Almotriptan is combined with Pyrantel.]
[J04AK01, pyrazinamide, Pyrazinamide may decrease the excretion rate of Almotriptan which could result in a higher serum level.]
[R06AC01, pyrilamine, The risk or severity of adverse effects can be increased when Almotriptan is combined with Mepyramine.]
[P01BD01, pyrimethamine, The metabolism of Almotriptan can be decreased when combined with Pyrimethamine.]
[C01BA01, quinidine, The metabolism of Almotriptan can be decreased when combined with Quinidine.]
[P01BC01, quinine, The metabolism of Almotriptan can be decreased when combined with Quinine.]
[A02BA02, ranitidine, The metabolism of Almotriptan can be decreased when combined with Ranitidine.]
[C02AA01, rescinnamine, Almotriptan may decrease the antihypertensive activities of Rescinnamine.]
[C02AA02, reserpine, The risk or severity of adverse effects can be increased when Almotriptan is combined with Reserpine.]
[J05AP01, ribavirin, Ribavirin may decrease the excretion rate of Almotriptan which could result in a higher serum level.]
[J04AB02, rifampin, The metabolism of Almotriptan can be increased when combined with Rifampicin.]
[R03AC05, rimiterol, The risk or severity of hypertension can be increased when Almotriptan is combined with Rimiterol.]
[G02CA01, ritodrine, The risk or severity of hypertension can be increased when Ritodrine is combined with Almotriptan.]
[N06AX01, 5-hydroxytryptophan, The risk or severity of adverse effects can be increased when Almotriptan is combined with Oxitriptan.]
[N02BA05, salicylamide, The risk or severity of hypertension can be increased when Almotriptan is combined with Salicylamide.]
[A07EC01, sulfasalazine, The risk or severity of hypertension can be increased when Sulfasalazine is combined with Almotriptan.]
[S01BC08, salicylic acid, The risk or severity of hypertension can be increased when Almotriptan is combined with Salicylic acid.]
[S01FA02, scopolamine, Almotriptan may increase the central nervous system depressant (CNS depressant) activities of Scopolamine.]
[N05CA06, secobarbital, The metabolism of Almotriptan can be increased when combined with Secobarbital.]
[N04BD01, selegiline, The metabolism of Almotriptan can be decreased when combined with Selegiline.]
[J01GB08, sisomicin, Almotriptan may decrease the excretion rate of Sisomicin which could result in a higher serum level.]
[A12CD01, sodium fluoride, Almotriptan may decrease the excretion rate of Sodium fluoride which could result in a higher serum level.]
[V04CC01, sorbitol, Almotriptan may decrease the excretion rate of Sorbitol which could result in a higher serum level.]
[C07AA07, sotalol, The metabolism of Sotalol can be decreased when combined with Almotriptan.]
[L01CD04, cabazitaxel, The metabolism of Cabazitaxel can be decreased when combined with Almotriptan.]
[C03DA01, spironolactone, The metabolism of Almotriptan can be decreased when combined with Spironolactone.]
[V04CH02, indigo carmine, Almotriptan may decrease the excretion rate of Indigotindisulfonic acid which could result in a higher serum level.]
[N05CC01, chloral hydrate, The risk or severity of adverse effects can be increased when Almotriptan is combined with Chloral hydrate.]
[N03AG01, valproic acid, The risk or severity of adverse effects can be increased when Valproic acid is combined with Almotriptan.]
[H02CA04, levoketoconazole, The metabolism of Almotriptan can be decreased when combined with Levoketoconazole.]
[D10AX03, azelaic acid, Azelaic acid may decrease the excretion rate of Almotriptan which could result in a higher serum level.]
[R03BB01, ipratropium bromide, Almotriptan may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
